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The defining feature of malignant neoplasms which distinguishes them from 
benign tumors is the capacity for metastasis. In fact, tumor metastasis is the leading 
cause of death in cancer patients. The metastasis of tumors is a highly complex and 
multi-step process that requires several interdependent biological events, such as 
angiogenesis, adhesion, invasion, migration and proliferation at a secondary site. 
Therefore, identification of chemopreventive agents with multiple biological activities 
that are non-toxic and effectively act to interrupt various steps of metastatic cascade 
could be of clinical significance. Emodin, an active component from the rhizome of 
Rheum palmatum, has been explored as a highly potential candidate for cancer 
chemoprevention and chemotherapy for many years. One of main mechanisms 
involved is the strong inhibitory effect of emodin on several critical kinases, such as 
Her-2/neu kinase, casein kinase II, and protein kinase C. However, its anti-metastatic 
properties are less well studied. Thus, the main objective of this study is to 
systematically clarify the properties of emodin against tumor metastasis. The following 
investigations have been conducted: (i) inhibitory effect of emodin on cancer cell 
invasion; (ii) suppression of emodin on cancer cell migration; and (iii) inhibitory 
property of emodin on cancer cell adhesion.  
First, emodin was observed to inhibit the invasiveness of human cancer cells by 
suppressing matrix metalloproteinase-9 expression through inhibition of activator 
protein-1 (AP-1) and nuclear factor kappaB (NF-κB) signaling pathways. The results 
reveal that emodin suppresses the phosphorylation of inhibitor of kappaB and NF-κB 
 xi 
activation, and also, decreases the phosphorylation of extracellular signal-regulated 
kinase 1/2 and c-Jun N-terminal kinase, and subsequent AP-1 activation.  
Second, emodin inhibits the epithelial growth factor-induced cell migration in 
various cancer cells. In searching for underlying mechanisms, phosphatidylinositol 
3-kinase (PI3K) was found to be the molecular target of emodin. Moreover, emodin 
blocks cell migration by interference with the formation of Cdc42/Rac1 and the 
p21-activated kinase complex.  
Third, emodin also suppresses cancer cell adhesion, another critical step of tumor 
metastasis. This inhibition is mainly through decreasing the cholesterol level in the 
membrane lipid rafts and subsequent disruption of the lipid rafts-associated integrin 
signaling pathway, including integrin clustering and focal adhesion formation. 
In summary, the present study provides convincing experimental evidence 
demonstrating the inhibitory effect of emodin on tumor cell invasion, migration and 
adhesion. These findings suggest that emodin interferes with tumor metastasis at 
several pivotal points and it could be used as a chemotherapeutic agent in preventing 
metastasis of human cancers. 
 xii 
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1.1 Introduction: rhubarb and emodin 
Rhubarb (Rheum officinale or R. palmatum) has been an important ingredient in 
Chinese and Tibetan traditional prescriptions for thousands of years (Fig. 1.1). It has 
the effect of purgation, loosening the bowels, curing gastric and renal disorders, 
removing bacterial dysentery, promoting blood circulation and improving blood stasis 
[Huang, 1999]. Besides its pharmacological values, rhubarb is also a vegetable with a 
unique taste that makes it a favorite in many pies and desserts. 
The major active chemical constituents of rhubarb include anthraquinones, oxalic 
acid, and tannins [Shang and Yuan, 2002]. The pharmaceutically relevant compounds 
in rhubarb are mainly anthraquinone derivatives, including emodin, rhein, aloe-emodin, 
physcion, chrysophanol and their glucosides. Among these anthraquinones, emodin has 
been under intensive investigations since last decade, and it has been shown that 
emodin possesses a number of biological activities, which will be discussed in detail in 
the following sections. 
1.2 Chemical structure and metabolism of emodin 
Being one of the major anthraquinone compounds of rhubarb, emodin 
(3-methyl-1,6,8-trihydroxyanthraquinone, Fig.1.1) has been shown to display anti-viral, 
anti-microbial, hepatoprotective, anti-inflammatory, anti-ulcerogenic, and anti-tumor 
properties [Huang et al., 1992; Minyi, 1992; Lin et al., 1996]. 
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Fig. 1.1 Rhubarb and chemical structure of emodin. 
 
Absorption, excretion, tissue distribution and metabolism of emodin were studied 
after a single oral administration of [14C]emodin (50 mg/kg) to rats [Bachmann and 
Schlatter, 1981]. Emodin was rapidly absorbed from the gastrointestinal tract. 
Radioactivity in the peripheral blood reached a peak 2 hr after administration, and 
subsequently decreased to 30% of the peak value within 24 hr. Urinary excretion 
amounted to 18% dose in 24 hr and to 22% in 72 hr and most metabolites found in 
pooled urine were free emodin and emodic acid. In 24 hr, 48 % and in 120 hr, 68 % of 
the emodin intake was excreted in the faeces, mostly in the free anthraquinone form. In 
two cannulated rats biliary excretion reached a maximum at approximately 6 hr and 
 4 
amounted to 49% dose within 15 hr; 70% of biliary activity was in the form of 
conjugated emodin. Besides, the content of radioactivity in most organs decreased 
significantly between 3 and 5 days.  
Another study revealed that administration of emodin (10mg/kg) to rabbits by i.v. 
bolus resulted in a serum profile which could be well described by a two-compartment 
model. The distribution half life of emodin was 6.8 min and the elimination half life 
was 227 min [Liang et al., 1995].  
1.3 Pharmacological properties of emodin 
1.3.1 Gastrointestinal activities 
Studies have revealed that emodin is a potent agent in the management of clinical 
and experimental acute pancreatitis. This might be ascribed to the effect of emodin on 
the up-regulation of transforming growth factor beta1 (TGF-β1) and epidermal growth 
factor (EGF) gene expression, which leads to increased protein content, thus 
accelerating pancreatic repair and regeneration [Gong et al., 2002]. 
Besides, emodin enhanced the function of small intestinal peristalsis of mice by 
mechanisms of promoting secretion of motilin (an important endogenous peptide 
regulator of gastrointestinal motor function), lowering the content of somatostatin and 
inhibiting Na+-K+-ATPase activity of small intestinal mucosa [Zhang et al., 2005]. 
Moreover, emodin showed protective effect on carbon tetrachloride as well as 
D-galactosamine (D-GalN)-induced liver damage [Lin et al., 1996]. Emodin was also 
effective to prevent and treat nonalcoholic fatty liver. Its therapeutic mechanism could 
be associated with increasing expression of peroxisome proliferator activated receptor 
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(PPAR), an important transcription factor that regulates adipogenic differentiation and 
glucose homeostasis [Dong et al., 2005]. 
1.3.2 Renal protective effect 
Mesangial cells play an important role in the genesis of the cellular damage 
observed in nephritis. Lesion sites in the kidney are often characterized by an increase 
in the number of mesangial cells and the amount of surrounding mesangial matrix 
[Mene et al., 1989]. Emodin showed strong suppressive effect on human mesangial cell 
proliferation activated by interleukin (IL)-1β and IL-6 [Kuo et al., 2001b]. Besides, 
emodin ameliorated the high glucose-induced matrix synthesis in mesangial cells via 
suppression of the activation of protein kinase C (PKC) and cAMP response element 
binding protein [Chan et al., 2003]. Furthermore, emodin inhibited proliferation and 
promoted apoptosis of renal fibroblasts isolated from lupus nephritis patients. This may 
be important in suppressing interstitial fibrosis, thus improving prognosis of lupus 
nephritis [Liu et al., 2000].  
1.3.3 Anti-fungal, anti-trichomonal and anti-microbial effects 
Emodin showed significant antifungal activity against Botrytis cineria, Erysiphe 
graminis, Phytophthora infestans, and Rhizoctonia solani [Kim et al., 2004]. However, 
another report noted that emodin had no obvious effect on Sclerotinia minor, 
Sclerotinia sclerotiorum, and Botrytis cinerea [Chrysayi-Tokousbalides and Kastanias, 
2003]. Emodin delayed the development of subcutaneous abscesses due to infection of 
Trichomonas vaginalis and inhibited the intravaginal infection of trichomonas through 
oral administration [Wang, 1993]. Meanwhile, it was reported that emodin suppressed 
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the growth of Helicobacter pylori, which is closely related to peptic ulcer disease. This 
inhibitory effect might be through its induction of DNA damage [Wang and Chung, 
1997].   
1.3.4 Other pharmacological effects 
Myocardial protective effect of emodin was observed using isolated perfused rat 
hearts after ischemia-reperfusion (IR) injury [Yim et al., 1998]. Pretreatment with 
emodin per se at 1.2mmol/kg was found to protect against IR injury as assessed by 
measuring the extent of lactate dehydrogenase (LDH) leakage. This myocardial 
protection of emodin was associated with significant reduction in the extent of 
IR-induced reduced glutathione (GSH) depletion [Yim et al., 1998].  
The muscle contraction induced by emodin was studied in the mouse isolated 
diaphragm and sarcoplasmic reticulum membrane vesicles [Cheng and Kang, 1998]. 
This effect was due to the oxidation of the ryanodine receptor and influx of extracellular 
Ca2+ through voltage-dependent Ca2+ channels of the plasma membrane, and 
subsequent release of Ca2+ from sarcoplasmic reticulum. Another study showed that 
emodin modulated the intracellular Ca2+ concentration in isolated brain cells through 
blocking Ca2+ dependent release of glutamate from the Schaffer collaterals in the 
hippocampal area [Lin and Jin, 1995]. 
1.4 Anti-cancer activities of emodin 
Besides its various pharmacological activities, recent studies on emodin have been 
mostly focused on its anti-tumor properties. These efforts lead to unraveling both the 
effect of emodin against cancer development and the underlying molecular 
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mechanisms involved. Some of these reports are summarized in the following sections. 
1.4.1 Inhibition of cell proliferation and cell cycle arrest  
A number of studies have demonstrated that emodin inhibited the growth and 
proliferation of various cancer cells derived from different tumors, such as breast, lung, 
cervical, colorectal and prostate cancers [Chan et al., 1993; Zhang et al., 1995; Chang et 
al., 1996; Kuo et al., 1997; Cha et al., 2005]. After comparison with other 
anthraquinone derivatives, including emodin 1-O-β-D-glucoside, physcion, and 
physcion 1-O-β-D-glucoside, C1 and C3 position of emodin was believed to be 
important for its anti-tumor function [Kuo et al., 1997]. 
Meanwhile, emodin displayed over 25-fold differential cytotoxicity against 
ras-transformed bronchial epithelial cells to the normal human bronchial epithelial 
cells [Chan et al., 1993]. Emodin also evoked a less or no cytotoxic effect in several 
normal cells, including HBL-100 cells derived from normal human breast tissue 
[Zhang et al., 1995], human fibroblast-like lung WI-38 cells and three primary cultured 
rat normal cells [Shieh et al., 2004]. These observations suggest that normal cells might 
be more resistant to emodin-induced cytotoxicity than cancer cells.  
Cells contain various pathways designed to protect them from the genomic 
instability or toxicity that can result when their DNA is damaged. A pivotal role in this 
response is played by checkpoint proteins that control the normal passage of cells 
through the cell cycle. During tumorigenesis, tumor cells frequently loose checkpoint 
controls and this facilitates the development of the tumor [Deane et al., 2005]. Thus, 
one of the important approaches for cancer chemotherapy is to regulate cell cycle 
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progression. The effect of emodin on cell cycle has been demonstrated on various 
cancer cells. Emodin induced G2/M arrest in v-ras-transformed cells [Chan et al., 1993], 
and HepG2/C3A cells, a human hepatoma cell line [Shieh et al., 2004]. Elevation of 
p53 and p21 expression might be involved in this G2/M arrest [Shieh et al., 2004]. In 
addition to G2/M arrest, emodin was reported to block the G1 to S phase of the cell 
cycle in human colon carcinoma HCT-15 cells [Kamei et al., 1998] and breast cancer 
MDA-MB-453 cells [Zhang et al., 1995].  
1.4.2 Induction of apoptosis in cancer cells 
The process of apoptosis, or so-called programmed cell death, is fundamental in the 
developmental and homeostatic maintenance of complex biological systems. 
Dysregulation or failure of normal apoptotic mechanisms will contribute to the 
transformation of cells and provide a growth advantage to cancer cells. It is 
characterized by cell shrinkage, chromatin condensation, DNA fragmentation and the 
activation of specific cystein proteases known as caspases. Two apoptotic pathways 
converge on caspase-3: one involving caspase-8 and the other involving mitochondrial 
release of cytochrome c and activation of caspase-9 [Fischer and Schulze-Osthoff, 
2005].  
Apoptosis could be a potential general mechanism of the anti-proliferative and 
anti-neoplastic effects of emodin. As shown in Table 1.1, a number of studies have 
demonstrated that emodin is capable of inducing apoptotic cell death in various cancer 
cells. Several studies revealed that emodin-induced apoptosis was mediated by reactive 
oxygen species (ROS) generated from the semiquinone [Jing et al., 2002; Su et al., 
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2005], although there was a report noted that emodin induced apoptosis 
ROS-independently [Chen et al., 2002]. It is believed that the quinoid structure of 
emodin could be activated to the semiquinone radical intermediate, which in turn could 
react with oxygen to generate ROS and induce oxidative stress [Su et al., 2005]. The 
generation of ROS may contribute to mitochondrial damage, reduction of 
mitochondrial transmembrane potential, release of cytochrome c and Smac, and 
subsequent caspase activation and apoptosis [Bras et al., 2005].  
To further explore the mitochondria-related pathway involved in emodin-induced 
apoptosis, several groups examined the role of Bcl-2 family members. Emodin 
treatment significantly increased expression level of pro-apoptotic protein, Bax and 
Bak, and caused Bax mitochondrial translocation and subsequent apoptosis [Jing et al., 
2002]. Besides, anti-apoptotic protein Bcl-2 was also involved in emodin-induced 
apoptosis: first, emodin caused a significant decrease in Bcl-2 expression; second, 
ectopic expression of Bcl-2 markedly blocked emodin-induced apoptosis [Su et al., 
2005]. Additionally, PKC-δ and ε may also be involved in emodin-induced apoptosis. It 




Table 1.1 Induction of apoptosis by emodin in human cancer cells 
 




(10-50 μM) up to 72 hr ROS generation, inactivation of ERK and Akt, decrease of Bcl-2, 
increase of Bax, disruption of mitochondrial membrane potential, 
apoptosis 
[Su et al., 2005] 
Human cervical 
carcinoma Bu 25TK 
(25-100 μM) up to 48 hr Activation of caspases-3 and 9, caspase-8 independence, 
induction of apoptosis 
[Srinivas et al., 
2003] 
Human hepatoma cells 
Mahlavu 
(10-150 μM) up to 72 hr ROS generation, reduction of mitochondrial membrane potential, 
induction of apoptosis 
[Jing et al., 2002] 
Human myelogenous 
leukemia cells HL-60 
(10-80 μM) up to 12 hr Decrease of Mcl-1, no change of Bcl-2, Bcl-XL, Bax and Bad, 
ROS independence, apoptosis 
[Chen et al., 2002] 
Human lung squamous 
carcinoma cells CH27; 
human lung non-small 
carcinoma cells H460 
(1-50 μM) up to 72 hr Increase and translocation of Bak and Bax, no change of Bcl-XL, 
activation of caspase-3, 9, 8, decrease of PKC δ and ε, apoptosis 
[Lee, 2001b; Lee, 
2001a] 
Human hepatoma cells 
HepG2/C3A 
(20-60 μM) up to 48 hr Activation of caspase 3, p53 dependence, apoptosis [Shieh et al., 
2004] 
Human cervical 
carcinoma cells HeLa  
As2O3 combined with 
(0.5-10 μM) emodin up to 
72 hr 
Generation of ROS, inhibition of NF-κB and AP-1, sensitization 
of HeLa cells to As2O3-induced apoptosis 
[Yi et al., 2004] 
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1.4.3 Anti-metastatic activity 
The high mortality rates associated with cancer are caused by the metastatic spread 
of tumor cells from the original site. Several interdependent biological events required 
for tumor metastasis: angiogenesis and lymphangiogenesis, adhesion, invasion, 
migration, and proliferation at ectopic site.  
Although many works have been done to explore the anti-tumor effect of emodin, 
only a few of them focused on the effect of emodin against tumor metastasis. In terms 
of cell adhesion, emodin inhibited tumor necrosis factor alpha (TNF-α)-induced 
expression of cell surface adhesion proteins, including intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which are 
essential to cell adhesion, migration and inflammation [Kumar et al., 1998]. This 
inhibition is mainly through the suppression of emodin on nuclear factor kappaB 
(NF-κB) activation [Kumar et al., 1998].  
The mechanisms of emodin against cancer cell migration and invasion are 
similarly unknown. No solid study was conducted to investigate the possible effect of 
emodin on cancer cell migration. In terms of invasion, it was reported that 
overexpression of Her-2/neu oncogene could enhance tumor metastatic potential, 
including the invasive ability to penetrate the basement membrane [Yu et al., 1994]. 
Thus, as a Her-2/neu tyrosine kinase inhibitor, emodin has been shown to suppress cell 
invasion in Her-2/neu transformed NIH3T3 cells [Zhang et al., 1998]. Another report 
noted that emodin inhibited the invasion of PG lung cancer cells. The activity of 
matrix metalloproteinase (MMP)-9, a gelatinase closely involved in cancer cell 
 12 
invasion, was observed to be suppressed by emodin [Wang and Zhen, 2001]. However, 
no further molecular mechanism was studied in their work.    
In term of angiogenesis, mainly due to its inhibition on casein kinase II (CKII), 
emodin showed significant suppressive effect on angiogenesis and retinal 
neovascularization. It stabilized retinal endothelial cell tubes on basement membrane 
matrix and inhibited secondary sprouting and cell proliferation. Besides, emodin 
inhibited the proliferation of endothelial cells from bovine aorta, blocked the 
endothelial cell cycle at G2/M phase and induced apoptosis [Ljubimov et al., 2004].  
Emodin had been explored for many years as a highly potential candidate for 
cancer chemoprevention and chemotherapy. However, in contrast to large number of 
studies on emodin-induced apoptosis and suppression of cell proliferation, no 
systematic study has been carried out to clarify its effect against tumor metastasis and 
the molecular mechanism involved. Many key questions still remain unclear. For 
example, how does emodin inhibit the invasiveness and MMP-9 activity in cancer 
cells? Can emodin inhibit cancer cell migration and what might be the possible 
mechanisms? What is the molecular mechanism involved in its effect against tumor 
cell adhesion? Further studies are needed to clarify these questions and provide 
comprehensive information about the anti-metastatic effect of emodin. 
1.4.4 Anti-inflammatory effect 
Chronic inflammation promotes cancer development during tumor progression 
[Coussens and Werb, 2002]. A variety of chemicals with anti-inflammatory effect can 
protect animals against the toxic and carcinogenic effects of chemicals and microbes 
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[Yang et al., 2001]. Emodin was reported to suppress the proliferation of several 
activated cell lines, including primary human T lymphocytes [Kuo et al., 2001a], 
mononuclear cells [Huang et al., 1992], mesangial cells [Kuo et al., 2001b] and RAW 
264.7 macrophages [Li et al., 2005]. The mechanisms of this inhibition are related to (a) 
the attenuation of IL-2 and TNF-α mRNA level, (b) decrease of cytokine production 
including IL-1, IL-2, IL-4 and TNF-α, (c) hydrogen peroxide generated from 
semiquinone, and (d) suppression of NF-κB activation. Besides, the structure-activity 
relationship studies indicate that the free hydroxyl group at the β-position of the 
anthraquinone nucleus played an essential role in the inhibitory effect of emodin on 
inflammation [Huang et al., 1992].  
1.4.5 Anti-mutagenic effect 
Emodin was reported to inhibit the formation of 1-nitropyrene-induced DNA 
adducts in Salmonella typhimurium (TA98) and SOS chromotest with E. coli PQ37, 
suggesting that emodin may act as a blocking and/or suppressing agent to decrease the 
direct-acting mutagenicity of 1-nitropyrene [Su et al., 1995]. Also, emodin markedly 
inhibited benzo[α]pyrene-mediated DNA damage in comet assay system [Wu et al., 
2001]. 
Nucleotide excision repair (NER) is the main DNA repair pathway by which 
mammalian cells remove UV- or carcinogen-induced DNA damage. Emodin increased 
unscheduled DNA synthesis for UV-induced damage and reduced the cytotoxicity of 
cisplatin to W138 cells, a human lung diploid fibroblast cell line, suggesting that 
emodin may promote NER activity [Chang et al., 1999]. Emodin also increased the 
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expression of key subunits of NER complex. Besides, since UV-induced NER is Ca2+ 
dependent, emodin elevated the Ca2+ influx which might lead to its enhancement of 
DNA repair [Chang et al., 1999].  
In addition to NER enhancement, inhibition of cytochrome P4501A1 activity 
might be another mechanism by which emodin displays its anti-mutagenic effect. 
Emodin was reported to suppress the mutagenicity of one of the heterocyclic amines, 
3-amino-1-methyl-5H-pyrodo[4,3-b]indole, through inhibiting the activity of 
cytochrome P4501A1 [Sun et al., 2000]. 
1.4.6 Sensitization effect 
Chemoresistance is of outstanding importance for the limited results of 
chemotherapy in various tumors. Different combinations of chemotherapeutic drugs 
may offer great potential for improving anti-tumor responses in various carcinomas. 
As a Her-2/neu tyrosine kinase inhibitor, emodin suppressed the proliferation of 
Her-2/neu-overexpressing lung cancer cells and sensitized these cells to 
chemotherapeutic drugs, such as cisplatin, doxorubicin, and VP16 [Zhang and Hung, 
1996]. Emodin also acted in synergy with celecoxib to suppress the growth of rat 
cholangiocarcinoma, which arises from the epithelial lining cells of intra- and 
extra-hepatic bile ducts, in a cyclooxygenase-2 independent manner [Lai et al., 2003]. 
This combination treatment decreased the phosphorylation level of Akt, leading to 
increased caspase-9 and 3-mediated apoptosis. Besides, emodin has been reported to 
sensitize different tumor cells to arsenic trioxide, including EC/CUHK1 (human 
esophageal carcinoma cell), HeLa, U937, and NB4 (human myeloid leukemic cell) 
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[Yang et al., 2003; Yang et al., 2004; Yi et al., 2004]. It is worth mentioning that 
non-tumor human fibroblasts were not responsive to the combination treatment of 
emodin and arsenic trioxide [Yang et al., 2004]. Another report revealed that, as a CKII 
inhibitor, emodin sensitized cancer cells to TRAIL-induced apoptosis through 
suppressing CKII activity and subsequent NF-κB-mediated expression of Bcl-XL and 
c-FLIP [Ravi and Bedi, 2002].  
The underlying mechanisms involved in these sensitization effects might be 
through: (a) inhibition of Her-2/neu kinase; (b) generation of ROS; (c) suppression of 
NF-κB activation. Among them, ROS generation by emodin has been suggested to 
play an important role in its synergistic effect with other chemotherapeutic agents. 
Yang et al. noted that the increased ROS induced by emodin and arsenic combination 
treatment mediated both the enhancement of pro-apoptosis and the inhibition of 
anti-apoptosis [Yang et al., 2004]. The enhancement of pro-apoptosis included the 
collapse of the mitochondrial transmembrane potential, the release of cytochrome c, 
and the activation of caspase 9 and 3. The inhibition of anti-apoptosis included 
suppressing NF-κB activation and expression of survivin, NF-κB-specific 
anti-apoptosis protein [Yang et al., 2004]. After examining the cDNA 
microarray-based global transcription profiling, the same group of workers revealed 
that the increased ROS level generated by emodin contributed to significant 
expression alteration of genes, which are critical in regulating related signal 
transduction, organelle functions, cell cycle checkpoint and cytoskeleton. The changes 
finally sensitized the cancer cells to arsenic cytotoxicity [Wang et al., 2005].  
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On the other hand, emodin failed to show significant chemosensitizing effect to 
carboplatin, an alkylating anti-neoplastic agent, in primary cells from an ovarian 
carcinoma overexpressing Her-2/neu and topoisomerase IIα [Hengstler et al., 1999]. 
This might be due to the character of high topoisomerase IIα expression level in this 
cancer cell line. It was reported that the inhibition of topoisomerase IIα significantly 
decreased the clonogenic survival of the cells [Stevnsner and Bohr, 1993]. High 
topoisomerase IIα might influence chemosensitivity by changing the accessibility of 
DNA sequences for alkylation and subsequent repair.  
1.4.7 Other anti-tumor effects 
Glutathione S-transferase P1-1 (GSTP1-1) is a phase II metabolic enzyme. It is 
also involved in carcinogenesis and resistance of cancer cells to oxidative stress and 
chemotherapeutic drugs. Emodin decreased TNF-α and 
12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced GSTP1-1 gene expression 
through inhibiting NF-κB and activating protein-1 (AP-1) binding onto GSTP1-1 
promoter in K562 and U937 leukemia cells [Duvoix et al., 2004]. This could 
contribute to the reduction of the incidences of glutathione related drug resistance in 
human cancers. 
Besides, emodin inhibited androgen receptor (AR) transcriptional activity by 
preventing AR nuclear translocation. This resulted in decreased association of AR and 
heat shock protein 90, which regulated the protein stability of ligand-unbound AR, but 
increased association of AR and MDM2, which in turn induced AR degradation 
through proteasome-mediated pathway in a ligand-independent manner [Cha et al., 
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2005]. Through this mechanism, emodin suppressed prostate cancer cell growth in 
vitro and prolonged the survival of prostate cancer-producing C3(1)/SV40 transgenic 
mice in vivo.  
1.4.8 In vivo anti-cancer effect  
A number of studies have been carried out to test the anti-tumor effect of emodin 
using in vivo animal models (as shown in Table 1.2). When administered 
intraperitoneally, emodin was found to reduce tumor weight in the EC/CUHK1 (a cell 
line derived from esophageal carcinoma) [Yang et al., 2004] or PC3-AR (an androgen 
receptor-overexpressing PC3 cell line) xenografts in nude mice [Cha et al., 2005]. 
Moreover, C3(1)/SV40 transgenic mice, a strain that will develop androgen receptor 
(AR)-positive prostate cancer in male, was used as a model to further explore the 
anti-tumor effect of emodin in vivo [Cha et al., 2005]. Emodin-treated mice had 
significant longer survival and better body weight gain than the control group. It is 
worth mentioning that emodin not only had low drug toxicity but also maintained the 
physical activity of transgenic mice by preventing tumor progression.  
As a tyrosine inhibitor, emodin has been shown to inhibit the growth of 
HER-2/neu-overexpressing MDA-MB-361 breast cancer cells, and also, sensitize 
these cells to taxol in a nude mice xenograft model [Zhang et al., 1999]. Since the 
tyrosine kinase activity of HER-2/neu is required for cell growth and taxol resistance, 
the synergistic effect of emodin plus taxol on tumor growth in mice might be due to 
decreasing tyrosine phosphorylation of p185neu. Meanwhile, emodin sensitized the 
EC/CUHK1 cell-derived tumors to arsenic trioxide with no apparent systemic toxicity 
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and side effects [Yang et al., 2004]. The combined treatment of emodin and arsenic 
trioxide attenuated the antioxidant system of the tumor cells and enhances apoptosis, 
and this may contribute to its anti-cancer efficacy. Moreover, tumor cells were usually 
more susceptible to the synergistic effect of emodin and arsenic trioxide, while 
non-tumor counterparts are not responsive. This selectivity might give a good reason 
for the low side effects and system toxicity of emodin in vivo.  
Besides, emodin exhibited potent inhibitory effect on two-stage carcinogenesis test 
of mouse skin tumors induced by nitric oxide donor, 
(±)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexeneamide as an 
initiator and TPA as a promoter. Also, emodin showed similar suppressive effect on 
tumor promotion induced by 7, 12-dimethylbenz[α]anthracene and TPA [Koyama et 
al., 2002]. This is consistent with the earlier reports that emodin showed high 
anti-tumor promoting activity using a short-term in vitro assay of the EBV-EA 





Table 1.2 The Anti-cancer Properties of Emodin using In vivo Animal Models 
 
Animal Models Treatments Outcomes References 
PC3-AR xenografts 
in nude mice 
40mg/kg/d emodin, 
i.p. 







maintain body weight 
gain 




Decrease of tumor 
weight 
EC/CUHK1 





with arsenic, i.p.  
Decrease of tumor size 
and weight 
[Yang et al., 
2004] 
Two-stage 
carcinogenesis test of 
mouse skin tumors 
0.0025% emodin in 
drinking water 














xenografts in nude 
mice  
40mg/kg/d emodin 
alone or combined 
with taxol, i.p. 
Inhibit tumor growth, 
prolong survival  




1.5 Molecular mechanisms involved in the anti-cancer effects of emodin 
1.5.1 Effects on NF-κB signaling 
NF-κB, one of the major molecular targets of chemopreventive phytochemicals, is 
a transcription factor involved in multiple cellular processes, including cytokine gene 
expression, cell adhesion, apoptosis and cancer metastasis [Bharti and Aggarwal, 
2002]. Because of the immunosuppressive and anti-inflammatory effects of emodin, 
researchers became interested in how emodin regulates NF-κB signaling pathways 
leading to inflammation. Kumar et al. reported that the inhibition of emodin on 
TNF-induced NF-κB activation was not due to its chemical modification of NF-κB 
subunits, but its suppressive effect of degradation of IκB, an inhibitory subunit of 
NF-κB molecules [Kumar et al., 1998]. NF-κB activation involves the participation of 
several intermediates, such as protein tyrosine kinases, reactive oxygen intermediates, 
and proteases. IκB kinases (IKKs), NF-κB inducing kinase and TNF 
receptor-associated factor 2 also play critical roles in regulating NF-κB activation [Liu, 
2005]. So far, the underlying mechanisms on how emodin inhibits the activation of 
NF-κB are rather limited. Further investigation is still needed to explore the exact role 
of NF-κB in the bioactivity of emodin. 
On the other hand, Chen et al. reported that emodin failed to block NF-κB binding 
and transcriptional activation induced by lipopolysaccharide in macrophage 
RAW264.7 cells [Chen et al., 2000]. The discrepancies might be due to different 
methodology or different cell lines they used.  
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1.5.2 Effects on protein kinases  
1.5.2.1 Inhibition of HER-2/neu tyrosine kinase 
The proto-oncogene HER-2/neu encodes a 185kd transmembrane tyrosine kinase 
growth factor receptor with homology to epidermal growth factor receptor (EGFR) 
[Chen et al., 2003; Menard et al., 2004]. The enhancement of HER-2/neu tyrosine 
kinase activity increases malignant phenotypes. Therefore, inhibition of the 
HER-2/neu tyrosine kinase activity may lead to the suppression of cell transformation 
and tumor growth.  
Emodin preferentially suppressed autophosphorylation and transphosphorylation 
activities of HER-2/neu tyrosine kinase, and subsequent decrease of p185neu 
phosphorylation in HER-2/neu-overexpressing breast cancer cells [Zhang et al., 1995; 
Zhang and Hung, 1996]. Moreover, emodin induced a significant differentiation 
change in MDA-MB-453 and AU-565 human breast cancer cells, which express high 
level of p185neu. On the other hand, no significant change could be observed in the 
MCF-7 cells, which expresses basal levels of p185neu. Meanwhile, Zhang et al. further 
demonstrated that p185neu tyrosine kinase activity is important for the chemoresistant 
phenotype of HER-2/neu-overexpressing cancer cells. Emodin sensitized these cells to 
chemotherapeutic drugs, such as cisplatin, doxorubicin, etoposide or paclitaxel in vitro 
[Zhang and Hung, 1996] and in vivo [Zhang et al., 1998].   
1.5.2.2 Inhibition of Protein kinase CKII  
Protein kinase CKII, probably the most pleiotropic member of the protein kinase 
family, plays important roles in the process of cell proliferation, transformation, and 
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differentiation [Olsten and Litchfield, 2004; Unger et al., 2004]. Unlike most of the 
Ser/Thr protein kinases whose substrates contain consensus sequences generally 
determined by basic and prolyl residues, substrates of CKII share unique 
phosphoacceptor sites specified by clusters of acidic residues [Olsten and Litchfield, 
2004; Unger et al., 2004].  
Emodin was first reported to be a specific inhibitor of CKII by Yim et al [Yim et al., 
1999], who were originally interested in the inhibitory effect of emodin on cdc2, a 
Ser/Thr protein kinase essential in the process of cell cycle. They unexpectedly found 
that emodin acted as a competitive inhibitor of CKII with respect to ATP, with an IC50 
value of 2μM. A follow-up structure study of the complex between emodin and CKII 
crystals revealed that emodin could penetrate into the active site of CKIIα, overlap the 
position occupied by ATP, and fill a hydrophobic pocket between the N-terminal and 
the C-terminal lobes. This leads to its inhibition of the binding of the natural 
co-substrates of CKII, in a competitive manner [Battistutta et al., 2000].  
1.5.2.3 Inhibition of other kinases 
In addition to Her-2/neu tyrosine kinase and protein kinase CKII, emodin also 
shows inhibitory effect on some other kinases, such as PKC, myosin-light-chain 
kinase (MLCK), casein kinase I and v-Abl [Jinsart et al., 1992; Fredenhagen et al., 
1995]. Among them, emodin acts as a modest inhibitor of PKC [Fredenhagen et al., 
1995; Yim et al., 1999; Lee, 2001b]. It inhibited the translocation of PKC-α from 
cytosol to plasma membrane in human peritoneal mesothelial cells [Chan et al., 2003]. 
Besides, the decrease in the expression of PKC-δ and ε may play a role in 
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emodin-induced apoptosis [Lee, 2001b]. It has been suggested that the mechanisms 
involved in PKC inhibition by anthraquinones include: (a) binding of quinones to the 
PKC regulatory domains; (b) binding between –SH groups of PKC cysteine residues 
and  the quinone moiety; (c) quinine-sensitized photodamage of PKC through 
photosensitization [Diwu et al., 1994].  
1.5.3 Emodin is an anti-oxidant or oxidant? 
In some cell-free experimental system, emodin was found to inhibit the superoxide 
radical generation [Ng et al., 2003], and lipid peroxidation using the thiocyanate 
method [Choi et al., 2000]. But it did not show inhibitory activity in reactive oxygen- 
and nitrogen-mediated reactions [Choi et al., 2000; Demirezer et al., 2001]. On the 
other hand, under cell culture experimental system, emodin has been reported as a free 
radical generator [Huang et al., 1992], which leads to its immunosuppressive effect 
[Huang et al., 1992] and induction of apoptosis [Yi et al., 2004; Su et al., 2005]. 
Exposure of HeLa cells to emodin elicited an immediate but transient increase of 
cellular ROS level and a moderate GSH reduction [Yi et al., 2004]. Quinones are 
highly redox active molecules, which can form a redox cycle with their semiquinone 
radicals, leading to the formation of ROS that include superoxide anion radical, 
hydrogen peroxide and hydroxyl radical [Pryor, 1982; Goulart et al., 2003; Watanabe 
and Forman, 2003]. The quinoid structure of emodin (Fig. 1.1) could be activated to 
the semiquinone radical intermediate, with in turn could react with oxygen to produce 
ROS. These studies suggest that emodin can serve as a natural and low toxicity ROS 

















The defining feature of malignant neoplasms which distinguishes them from 
benign tumors is the capacity for metastasis. In fact, tumor metastasis has been the 
leading cause of death in cancer patients. It is an extremely complex process by 
which tumor cells leave the primary tumor, transfer to a distant site through the 
circulation system, and establish a secondary tumor [Bogenrieder and Herlyn, 2003]. 
Due to its high mortality rate, it is necessary to have a better understanding of the 
genetic and molecular mechanisms of cancer metastasis, and to develop new 
diagnostic and therapeutic strategies towards malignant cancers. Although a huge 
variety of genetic basis of tumorigenesis is believed to exist, the essential steps for 
tumor metastasis are similar for all tumor cells. Thus, a therapeutic strategy blocking 
metastasis would be useful in treating cancers from different genetic origins.  
During the metastatic process, there are several interdependent biological steps 
(Fig. 2.1): angiogenesis and lymphangiogenesis, the generation of new blood or 
lymphatic vessels, not only provides the necessary nutrition for the primary tumor to 
grow, but also increases the chance for tumor cells to access the circulation system and 
colonize at a new site; cell invasion and migration, the process of tumor cells to 
degrade and migrate across ECM barriers, requires the lysis of matrix proteins by 
specific proteinases, and stimulation of cell motility; cell adhesion, which is also 
necessary during metastasis, allows tumor cells attach to extracellular matrix (ECM) 
components and to other cells; finally, cell proliferation at secondary sites needs the 




(Adopted from Tumor progression. Welch DR 1984) 
Fig. 2.1 The metastatic cascade. 
 
2.1.1 Angiogenesis and lymphangiogenesis 
Angiogenesis is the process of new blood vessel generation. It brings oxygen and 
nutrition to primary tumors, which are necessary for tumor cell proliferation. Besides, 
it is also a critical step for metastasis development. A rich vascularization might give 
more opportunities for cancer cells to enter the circulation system and metastasize. 
Another possible reason is that the new formed blood vessels are more permeable to 
tumor cells and might contribute to metastasis [Denijn and Ruiter, 1993]. Consistently, 
a number of studies reported a negative correlation between patient survival and the 
degree of vascularization in prostate [Silberman et al., 1997], breast [Gasparini, 1996], 
and skin tumors [Srivastava et al., 1988].  
Angiogenesis generally can be divided into three steps: proliferation of endothelial 
cells, breakdown of the ECM, and migration of endothelial cells [Streit and Detmar, 
2003]. These steps are controlled, at least in part, by angiogenic factors secreted by 
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tumor cells, which include TGF-α, vascular permeability growth factor, vascular 
endothelial growth factors (VEGF), fibroblast growth factors, and others. In fact, 
angiogenesis are complex interactions among the tumor cells, endothelial cells, and 
the ECM, which can be modulated by serine proteases and MMPs [Streit and Detmar, 
2003]. 
Additionally, lymphangiogenesis is also an important step in the progression of 
cancer. Detection of tumor metastasis to regional lymph nodes, as by analysis of 
sentinel lymph nodes, represents the first step of tumor dissemination and provides 
important information for staging, prognosis, and therapeutic regimens design 
[Bogenrieder and Herlyn, 2003]. Similar to angiogenesis, the generation of new 
lymphatic vessels is controlled by members of the VEGF family, VEGF-C, VEGF-D, 
and their receptor on the lymphatic endothelium, VEGFR-3 [Oliver and Detmar, 2002]. 
Consistently, recent works on animal tumor models also suggest that enhanced 
VEGF-C and VEGF-D promote tumor lymphangiogenesis and lymphatic spreading to 
regional lymph nodes [Karpanen et al., 2001; Stacker et al., 2001].  
2.1.2 Cancer cell invasion 
A fatal characteristic of malignant cancer cells is their ability to invade other 
tissues and spread to distant organs. The invasiveness of tumor cells, to a large extent, 
depends on their ability to degrade ECM proteins. This process is mediated by some 
proteases, which play crucial roles in tumor invasion and metastasis. The proteases 
involved in the process of ECM degradation can be classified into metallo-, serine-, 
and cysteine-proteinases according to structural characteristics of their active 
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enzymatic center [Mannello et al., 2005]. 
Increased expression of matrix metalloproteinases (MMPs) has been observed in 
different malignancies. MMPs are widely expressed in carcinomas and have been 
implicated in the increased ECM degradation that occurs in cancer [Folgueras et al., 
2004]. Indeed, many MMPs were first cloned from tumor cells [Kerkela and 
Saarialho-Kere, 2003]. The detailed functions and regulation of MMPs will be 
discussed further in section 2.2. 
Among the group of serine proteases involved in ECM degradation, most studies 
are focused on plasmin and plasminogen activators. The ubiquitous plasmin is 
synthesized as plasminogen, its inactive proform, and its activation is associated with 
the degradation of several matrix components, such as gelatin, fibronectin, and 
laminin [Mignatti and Rifkin, 1996]. Plasminogen can be activated by the 
urokinase-type plasminogen activator (uPA) or the tissue-type plasminogen activators 
[Mignatti and Rifkin, 1996].  
In comparison to the MMPs and the serine proteases, less investigation has been 
carried out to elucidate the importance of the matrix degrading cysteine proteases, 
cathepsin B, H, and L, which are associated with the plasma membrane of cancer cells. 
some in vitro studies showed that proteolytic activities of these acidic proteases were 
responsible for dermal connective tissue invasion and tumor formation in high 
invasive melanoma cells [Dennhofer et al., 2003]. Overexpression of cathepsin L 
increased the tumorigenicity of human melanoma cells and switched their phenotype 
from non-metastatic to highly metastatic status [Jean et al., 1996]. 
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2.1.3 Cancer cell migration 
The motility of tumor cells is another important aspect during cancer metastasis. It 
can be generally directed by extracellular factors, which can be classified into three 
categories: the autocrine motility factors, such as hepatocyte growth factor/scatter 
factor (HGF/SF) [Gherardi and Stoker, 1991]; ECM proteins, such as fibronectin 
[McCarthy and Furcht, 1984], vitronectin and collagen [Tchao, 1982]; and 
host-secreted growth factors, such as insulin-like growth factor-I [Stracke et al., 1988]. 
These factors induce a large variety of cellular response that includes rearrangement of 
actin and microtubule cytoskeletons, and vesicular transportation. 
The molecular mechanisms of cell migration have been extensively investigated in 
recent years. It is generally believed that the major driving force of migration is 
through extending the leading edge of protrusion or lamellipodia, establishing new 
adhesion site, contracting cell body and detaching adhesion at cell rear [Yamazaki et 
al., 2005]. All these steps implicate a huge number of signaling molecules, including 
Rho GTPases, phospholipases, tyrosine and Ser/Thr kinases and lipid kinases. Among 
these, the Rho GTPases seem to play a pivotal role in regulating the migration 
signaling transduction [Benitah et al., 2004] and the detailed mechanisms will be 
further discussed in section 2.3.   
2.1.4 Cancer cell adhesion 
During metastasis, tumor cells must be able to adhere to ECM components 
(cell-matrix interaction) and with other cells (cell-cell interaction) as well. Many 
studies have reported that changes in the adhesive properties of tumor cells correlate 
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with progression to tumor malignancy [Hynes, 1999].  
The integrin family plays an essential role in the adhesion of tumor cells to ECM. 
They are transmembrane receptors that recognize unique short amino acid sequences, 
such as Arg-Gly-Asp (RGD), in the ECM molecules including collagens, fibronectin, 
laminin, and vitronectin. Integrins are composed of two uncovalent-linked subunits α 
and β. The combination of different subunits determines ligand specificity [Guo and 
Giancotti, 2004]. Several ECM molecules can be recognized by more than one integrin. 
Integrins are involved in signaling transduction through phosphorylation of associated 
cytoskeleton components [Guo and Giancotti, 2004]. (Since the integrins have a 
critical role in cancer cell adhesion, detailed discussion is carried out separately in 
section 2.4)  
Besides integrin family, some other adhesion molecules have been implicated in 
the adhesion of tumor cells to bone marrow elements, which involves multiple 
recognition mechanisms: very late antigen-4 (VLA-4) and CD44 were reported to be 
involved in the attachment of tumor cells to bone marrow fibroblasts and endothelial 
cells, while ICAM-1 was essential in the binding of tumor cells to bone marrow 
macrophages [Okado and Hawley, 1995]. 
Additionally, E-cadherin, an adhesion molecule, may play a role in the suppression 
of metastasis. It appears to maintain homotypic cell-cell adhesion through interacting 
homophylically and forming adhering junctions. Its functional dimers on one cell can 
form stable molecular bonds with dimers on neighboring cells [Cavallaro and 
Christofori, 2001]. Loss or decrease of E-cadherin correlated with enhanced cancer 
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progression [Bussemakers et al., 1992]. 
2.1.5 Tumor proliferation at ectopic site 
To establish metastasis, tumor cells need to proliferate at the secondary site under 
regulation of various growth factors. For example, when metastasizing to bone, tumor 
cells can be stimulated by growth factors derived from bone marrow or osteoblasts 
[Guise, 2000]. Meanwhile, some tumors show decreasing dependence on exogenous 
growth factors when progressing to malignancy. For example, melanoma cells can 
produce many positive growth factors, such as basic fibroblast growth factor (bFGF) 
and IL-8, which function as autocrine stimuli of cell proliferation [Becker et al., 1989; 
Schadendorf et al., 1993].  
2.2 Matrix metalloproteinases 
2.2.1 Introduction 
During the metastatic process, proteolytic enzymes play critical roles by helping 
tumor cells enter the vascular and lymphatic systems and invading tissues at ectopic 
sites. Among all the proteolytic enzymes closely related in tumor invasion and 
metastasis, the members of MMPs have been the focus of many investigations due to 
their ability to cleave virtually any component of the ECM and basement membranes 
[Vihinen et al., 2005]. Besides, MMPs are believed to regulate multiple cellular 
functions including cell growth, apoptosis, and immune response by cleaving growth 
factor precursors, cell adhesion molecules and other bioactive molecules [Egeblad and 
Werb, 2002]. 
Sharing a diverse range of substrates, MMPs currently can be divided into several 
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subgroups according to their substrate specificity and structure: gelatinases, 
collagenases, stromelysins and stromelysin-like MMPs, matrilysins, membrane-type 
MMPs and other MMPs [Kerkela and Saarialho-Kere, 2003]. Among them, 
gelatinases (including MMP-2 and MMP-9) can degrade type IV, V, VII, X, XI and 
XIV collagens, gelatin, elastin, proteoglycan and fibronectin, and are believed to have 
a particularly important role in cancer invasion and metastasis [Kerkela and 
Saarialho-Kere, 2003].  
2.2.2 Physiological functions of MMPs 
Disruption of ECM barriers is critical for certain fundamental physiological events, 
to allow cell migration and matrix remodeling. MMPs can not only degrade 
components of ECM and basement membranes, but also release or process bioactive 
molecules [Brinckerhoff and Matrisian, 2002], which strongly support direct 
implication of MMPs in a number of biological functions, such as embryonic growth 
and tissue morphogenesis. Additionally, MMPs play a wide and complex role in 
angiogenesis. Endothelial cells can produce many kinds of MMPs, which are believed 
to be important for the formation of new blood vessels in both physiological and 
pathological conditions. For example, MMP-2 null mice showed decreased 
vascularization ability compared to wild-type controls [Itoh et al., 1998]. Meanwhile, 
MMP-2 and MMP-9 has been demonstrated to have synergistic effect during choroidal 
neovascularization in MMP-2/MMP-9 double knockout mice [Lambert et al., 2003].  
2.2.3 MMP roles in cancer 
The increase of expression and activity of MMPs has been reported in almost 
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every type of human cancers compared with normal tissue. This change correlates with 
advanced tumor stage, and increased invasion and metastasis. Meanwhile, many 
studies reported a negative association between MMPs and cancer prognosis [Egeblad 
and Werb, 2002]. These observations imply that MMPs are crucial in the progression 
of human cancer. 
MMPs are generally considered extremely important in cancer invasion and 
metastasis [Yoon et al., 2003]. During metastasis, cancer cells must cross several ECM 
barriers. They need to cross the epithelial basement membrane and invade the 
surrounding stroma, enter blood or lymphatic vessels, extravasate and finally establish 
new colonies at a secondary site. These processes, to a large extent, are mediated by 
degradation functions of MMPs. Consistently, in vivo studies suggest that 
down-regulation of MMP-9 suppressed the colony formation in the lungs of mice 
[Davidson et al., 1999] and similar reduction was observed in MMP-2 and MMP-9 
null mice as compared with wild-type mice [Adachi et al., 2001].  
During invasion process, the localization of MMPs to specific surface protrusions 
on the cell membrane is necessary for their ability to promote invasion. MMP-2 and -9 
was reported to localize to these protrusions through different mechanisms: MMP-2 
might be recruited by binding to αvβ3 integrin [Brooks et al., 1996]; whereas, MMP-9 
might be recruited by binding to CD44, a protein necessary for the protrusion 
formation during tumor cell migration and invasion [Garzetti et al., 1995]. 
2.2.4 Regulation of MMPs 
During the past decades blocking the undesired activities of MMPs in malignant 
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tumor has been an important anti-cancer strategy. Thus, it is necessary to understand 
the detailed mechanisms that regulate the expression and activity of MMPs in both 
normal and diseased conditions. This may, therefore, provide clues for the eventually 
rational therapeutic interventions [Jedinak and Maliar, 2005].  
It has been found that there are three major levels of endogenous regulation of 
MMPs: gene transcription, proenzyme activation and inhibition of their enzymatic 
activity [Nomura et al., 1996]. Among them, gene transcription plays a critical role in 
regulating the expressing and functioning of MMPs. In fact, stimulation of growth 
factors and cytokines-responsive MMP genes can result in many fold changes in 
mRNA and protein levels of MMP-9 and other similar growth factor-responsive 
MMPs, such as MMP-1, MMP-10 and MMP-12. These inducers include 
platelet-derived growth factor (PDGF), EGF, HGF/SF, bFGF, TGF-α and β, IL-1α and 
β, interferon-α and γ. Some oncogenes, hormones and various chemical agents (such 
as TPA) can also induce the expression of MMPs [Egeblad and Werb, 2002]. These 
stimuli activate certain transcription factors, such as AP-1 and NF-κB, and 
subsequently induce the expression of these growth-factor responsive MMPs (Fig. 
2.2). 
On the contrary, due to the lack of inducible promoter elements, such as binding 
site for the AP-1 transcription factor, MMP-2 is rather constitutively expressed in 
tissues with only modest up or down regulation under various conditions (Fig. 2.2) 
[Bjorklund and Koivunen, 2005]. Its activity is mainly regulated at a 
post-transcriptional level by interacting with tissue inhibitor of metalloproteinase-2 
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(TIMP-2) [Bernardo and Fridman, 2003].  
 
 
Fig. 2.2 Regulatory elements of promoter regions of several human MMP genes. 
 
2.2.4.1 AP-1 transcription factor 
AP-1 is a well-characterized transcription factor consisting of homodimers and/or 
heterodimers of the Jun and Fos gene families. It controls the transcription of several 
genes containing AP-1 sites (consensus sequence 5'-TGAG/CTCA-3'), also known as 
TPA-responsive elements. Different AP-1 dimers bind DNA with different affinities, 
which are thought to be responsible for the diverse biological effects of distinct AP-1 
complexes [Dhar et al., 2002].  
Several stimuli, such as growth factors, cytokines, stress signals and TPA, induce 
the binding of AP-1 to its target DNA sequence of various genes, including several 
MMPs family proteins MMP-9, MMP-1, MMP-10, and MMP-12. Regulation of AP-1 
activation can be achieved through changes in transcription of genes encoding AP-1 
subunits, control of the stability of their mRNAs, and post-translational processing. 
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The mechanism of post-translational control is most extensively documented through 
three distinct mitogen-activated protein kinase (MAPK) pathways, extracellular 
signal-regulated kinases (ERKs), Jun N-terminal kinases (JNK), and p38 (Fig. 2.3) 
[Bode and Dong, 2000]. After phosphorylation and activation, the MAPKs translocate 
to the nucleus, where they phosphorylate AP-1 subunits and thereby enhance its 
transactivation potential. 
2.2.4.2 NF-κB transcription factor 
NF-κB, another well-characterized transcription factor, is ubiquitously expressed 
in mammalian cells. The NF-κB family consists of five members: p50, p52, p65, c-Rel 
and RelB. These five subunits can homodimerize or heterodimerize in cytoplasm, 
combined with NF-κB inhibitory proteins (IκBs) in its inactive form. When stimulated, 
the IκB proteins are phosphorylated by IKKs, and subsequently degraded through the 
ubiquitin pathway [Lin and Karin, 2003]. IκB degradation exposes the DNA-binding 
domain and nuclear localization sequence of NF-κB and permits its stable 
translocation to the nucleus and the regulation of target genes. NF-κB, separated from 
the inhibitor, translocates into the nucleus, where it activates gene transcription by 
binding to its specific DNA sequence of certain genes, including some MMPs proteins. 
Decrease of MMP-9 expression was observed in cytokine-stimulated cells when 
NF-κB is maintained in the cytoplasm by constitutive levels of IκB [Bondeson et al., 
2000].  
2.2.4.3 Role of MAPKs in the regulation of MMP gene expression 
One group of proteins that mediate the transactivation of transcription factors is the 
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MAPKs. MAPK family is a group of serine/threonine kinases, consisting of JNKs, 
ERKs and p38 kinases. Generally, ERKs respond to growth factors, phorbol esters, 
and cytokines, while JNK and p38 kinases are strongly activated by various forms of 
stress, inflammatory cytokines and apoptotic signals [Fang and Richardson, 2005]. 
These stimuli first activate a group of protein kinases, named MAPK kinase kinases 
(MAPKKKs), which phosphorylate MAPK kinases (MAPKKs). In turn, MAPKKs 
would be responsible for the phosphorylation and activation of MAPKs. After being 
activated by MAPKKs, MAPKs translocate to the nucleus to phosphorylate and 
activate specific transcription factors (as shown in Fig 2.3). Activation of JNKs and 
ERKs can induce phosphorylation and activation of c-Jun, an important subunit of 
AP-1 [Leppa et al., 1998]. In addition to c-Jun, phosphorylation of c-fos, the other 
AP-1 subunit, by ERKs stabilizes the c-fos protein and increase the transactivation and 
transformation ability of c-fos. Besides, the ERKs pathway regulates the activity of 
PEA3 Ets transcription factors [O'Hagan et al., 1996], which cooperate AP-1 proteins 
in multiple MMP promoters.   
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Fig. 2.3 Illustration of MAPKs pathways leading to the activation of transcription 
factors related to MMPs gene expression. 
 
2.3 Rho GTPases 
2.3.1 Introduction 
One of the earliest responses of most cells to extracellular signals is the rapid 
reorganization of the actin cytoskeleton leading to the formation of motile structures, 
alteration in cell shape, and hence, to the changes in cell migration. In mammalian 
cells, generation of actin-based dynamic motile structures is regulated by the small 
GTPases of the Rho family. They are small, 20-30kDa monomeric GTP-binding 
proteins that are highly conserved throughout evolution among different organisms 
[Sahai and Marshall, 2002]. They serve as signaling switches in mediating many 
aspects of cell biology including cell migration, adhesion, apoptosis, and proliferation 
[Benitah et al., 2004]. So far, Rho-GTPase family has been reported to contain at least 
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23 members, with new members still being discovered. Among them, the 
best-characterized Rho-proteins are Rac1, Cdc42 and RhoA. Rac1 is important for the 
formation of actin-rich ruffles, called lamellipodia, and subsequent assembly of 
lamellipodia at the leading edge of the migrating cells. Cdc42 is essential for the 
extension of actin-rich spikes (also called filopodia) which are believed to sense tactic 
signals and then establish the directionality of movement. RhoA is related to the stress 
fibers formation, which is involved in the generation of contractile force, moving the 
cell body and tail behind the leading edge [Schmitz et al., 2000].  
Recently an increasing amount of evidence indicates that Rho GTPases play an 
essential role in tumor biology. Specifically, changes in the expression and activity 
level of Rho GTPases are proven to be critical factors in tumor cell metastasis [Benitah 
et al., 2004]. In fact, numerous studies have demonstrated that Rho GTPases are 
important in cell migration. Since migration is a critical component of the tumor 
metastatic phenotype, it is not surprising to observe that dysfunction of Rho GTPases 
would affect cancer metastatic process [Walker and Olson, 2005]. For example, 
overexpression of domain positive mutant Rac1 and Cdc42 has been reported to 
induce the development of distant lung metastasis in in vivo metastasis experiments 
[Michiels and Collard, 1999].  
2.3.2 Regulation of Rho GTPases activation 
Like other GTPases, the Rho-GTPase proteins localize to the inner plasma 
membrane by a C-terminal lipid modification [Hori et al., 1991]. This localization is 
necessary to their activation. Rho-proteins function as molecule switches and cycle 
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between GTP- and GDP-bound states. As shown in Fig. 2.4, the proteins might remain 
in inactive form with GDP binding until stimuli, such as growth factors, cytokines, and 
various cell adhesion events, promote GDP-GTP exchange and convert the proteins to 
active conformation. Meanwhile, GTP can be hydrolysed by the intrinsic GTPase of 
the proteins and the proteins would return to the basal inactive state [Sahai and 
Marshall, 2002]. During this cycle, binding to GTP and activation of the proteins is 
promoted by Rho guanine nucleotide exchange factors (GEFs), and GTP hydrolysis 
and consequent inactivation of the proteins is catalyzed by Rho-GTPase-activating 
proteins (GAPs). An additional aspect of regulation is provided by Rho-GDP 
dissociation inhibitors (GDIs), which could sequester GDP-bound Rho proteins in the 
cytoplasm away from the GDP-GTP cycle [Sahai and Marshall, 2002].  
 
 
Fig. 2.4 The Rho GTPase cycle. 
 41 
The activity of Rho-GTPases is regulated by signals originating from different 
classes of surface receptors including tyrosine kinase receptors, cytokine receptors, 
G-proteins-coupled receptors, and adhesion receptors. A variety of stimuli, for 
example, insulin, PDGF, and EGF, can strongly induce Rac1 and Cdc42 activation 
through respective tyrosine kinase receptors on the membrane [Ridley et al., 1992]. 
Despite different growth factors stimulation, a common component of these signaling 
cascades is PI3K, an intracellular signaling protein controlling multiple cellular 
activities and properties including proliferation, survival and motility [Sotsios and 
Ward, 2000]. It usually consists of two subunits: p85 (85 kDa regulatory subunit) and 
p110 (110 kDa catalytic subunit). Upon activation, PI3K phosphorylates PIP2, a 
constitutive membrane component, to create the lipid second messenger 
phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3, in turn, activates certain GEFs 
that promote GDP-GTP exchange of Rho GTPases. These GEFs include Vav, Soc, 
Tiam, PIX and SWAP-70 [Welch et al., 2003]. Indeed, a large body of evidence have 
demonstrated that PI3K is involved in Cdc42 and Rac1 activation using specific 
inhibitors wortmannin and LY294002 as well as domain negative forms of the kinase 
[Hawkins et al., 1995; Nobes et al., 1995]. Equally, the use of domain negative Rac1 
and Cdc42 mutants revealed that Rac1 and Cdc42 mediate many of the PI3K signaling 
pathways [Welch et al., 2003]. On the other hand, some evidence also showed that 
Rac1 can act upstream of PI3K [Keely et al., 1997]. However, the underlying 
mechanism is yet not clear. 
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2.3.3 Effectors of Rho GTPases 
A number of effector pathways are involved in mediating changes to actin 
rearrangement and migration downstream of Rho-GTPases [Schmitz et al., 2000]. 
The active GTP-bound proteins can interact with these effector proteins that propagate 
downstream signaling events which lead to the ultimate desired biological responses. 
Many Rho effector proteins are kinases, which control cellular functions by 
phosphorylating cellular targets. The most well-studied effector kinases are the 
p21-activated kinases (PAKs) [Vadlamudi and Kumar, 2003], which bind to active 
form of Cdc42 and Rac1, and the Rho kinases (ROCKs) [Hall, 1998], which bind to 
active RhoA. Besides, some other effectors are scaffold proteins, which control 
cellular functions through protein-protein interactions [Ridley, 2004].  
As a common target of both Rac1 and Cdc42, PAKs are a group of serine/ 
threonine kinases controlling actin and adhesion dynamics. Currently, the PAK family 
consist of six known members, among which PAK1 is closely related with Rho 
GTPases-mediated cell migration [Kumar and Vadlamudi, 2002]. As shown in Fig. 2.5, 
PAK contains an N-terminal p21 GTPase-binding-domain (PBD), which confers 
binding to Cdc42 or Rac1, and a C-terminal catalytic domain. The PAKs form 
complexes specifically with activated GTP-bound GTPases, and this leads to 
autophosphorylation and activation of PAKs [Zhao and Manser, 2005]. The functions 
of PAKs in Cdc42/Rac1-mediated cytoskeleton rearrangements and tumor metastasis 
have been under extensive investigation. Activated PAK catalyzed phosphorylation of 
myosin-II light chain at Ser19, and such phosphorylation was implicated in cell 
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retraction [Zeng et al., 2000]. Expression of catalytically active PAK1 increased 
myosin-light-chain phosphorylation in fibroblasts and in endothelial cells [Kiosses et 
al., 1999]. Besides, PAK1 phosphorylated LIM motif-containing protein kinase 
(LIMK) at threonine residue 508 within LIMK’s activation loop and increased 
LIMK-mediated phosphorylation of the actin regulatory protein cofillin, which lead to 
polymerization of actin [Edwards et al., 1999].  
 
 
Fig. 2.5 PAK domain structure. 
 
In addition to PAKs, Wiskott-Aldrich syndrome protein (WASP) is another 
important effector of activated Rac1 and Cdc42. WASP is one member of a distinct 
family of proteins that participate in the transduction of signals from the cell surface to 
the actin cytoskeleton [Snapper and Rosen, 1999]. WASP proteins possess a binding 
domain (CRIB, also called GBD) for the GTP-bound form of the small GTPase Cdc42 
or Rac1. Meanwhile, The C-terminal of WASP family members consists of a domain 
responsible for binding to and also activating the Arp2/3 complex, a potent nucleator 
of actin polymerization [Machesky et al., 1999]. Thus, WASP serves as an adaptor 
protein to couple Rho-GTPase activity to Arp2/3 binding, actin nucleation and 





Integrin receptors mediate cellular adhesion to ECM and the attachment of cells to 
each other. It becomes clearer recently that the biological significance of 
integrin-mediated adhesion is not simply a physical linkage of cells to ECM or other 
cells. It also plays an important role for cell survival and proliferation, and participates 
in diverse events such as inflammation, immunity, as well as, some pathological 
processes [Hood and Cheresh, 2002; Guo and Giancotti, 2004]. Each integrin consists 
of two transmembrane subunits: α and β. So far, the integrin family has been identified 
as many as 18 α and 8 β subunits, from which at least 25 different functional integrins 
are formed in human [Hood and Cheresh, 2002]. It is now generally believed that 
integrins can bind to different ligands, and different ligands can be recognized by more 
than one integrin heterodimers [Gille and Swerlick, 1996]. Certain integrins bind to 
counter receptors on other cells, such as the immunoglobulin-type superfamily 
(ICAM-1, ICAM-2 and vascular cell adhesion molecule 1), and subsequently mediate 
direct cell-cell adhesion [Danen, 2005].  
As shown in Fig. 2.6, both α and β subunits of integrin contain a large extracellular 
domain, a single short transmembrane domain and a non-catalytic cytoplasmic 
C-terminal domain of variable length. Some α subunits are proteolytically cleaved 
near the transmembrane domain and the two chains are connected by a disulfide bond. 
On the other hand, β subunits generally have 4 repeats of cystein-rich segments on the 
extracellular domain, not far from the transmembrane region. The ligand binding 
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activity of α and β subunit is established by noncovalent dimerization which is mainly 
mediated by the N-terminal regions. This noncovalent linkage directly leads to weak 
ligand binding affinity of integrin receptors, and this weak affinity is essential to allow 
cells to rapidly attach to and detach from the surrounding substrate and thus providing 
a molecular basis for cell migration and invasion [Danen, 2005]. 
 
Fig. 2.6 Integrins are heterodimeric cell surface receptors. 
2.4.2 Integrin expression 
Many malignant cancer cells undergo dramatic changes in the levels of integrin 
expression. Significant differences have been documented in surface expression in 
malignant tumors compared with pre-neoplastic tumors of the same type [Mizejewski, 
1999]. For example, integrin α6β4 was up-regulated in papilloma [Tennenbaum et al., 
1993] and thyroid carcinoma [Serini et al., 1996]. Integrin αvβ3 was strongly 
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expressed in malignant melanoma cells and angiogenic blood vessels, but weakly 
expressed on pre-neoplastic melanomas and quiescent blood vessels [Brooks et al., 
1994]. This increased expression correlated with the metastatic potential of several 
human cancer cells [Duan et al., 2004]. Whereas the expression of some integrins is 
up-regulated during tumorigenesis, expression of others is down-regulated. For 
example, the expression of integrin subunit α1, α6 and β4 was decreased, associated 
with the formation of neoplasms, in breast epithelial tissue [Mizejewski, 1999]. 
However, the underlying mechanism of these expression changes is not clear yet. 
2.4.3 Integrin functions 
Cells secrete and assemble an insoluble network of proteins, the ECM, which 
provides a scaffold for the organization of cells, as well as an extraordinary control on 
cell behavior [Hood and Cheresh, 2002]. These effects of ECM on cells are mainly 
mediated by integrins. These cell surface receptors bind to the components of ECM, 
thus mediating the cell adhesion to ECM. Meanwhile, the integrin ECM interaction 
also induce the reorganization of cytoskeleton and activation of specific intracellular 
signaling pathways [Hood and Cheresh, 2002]. With no intrinsic enzyme activity, 
integrins activate signaling pathways by co-clustering with kinases and adaptor 
proteins in focal adhesion complexes.  
Cell adhesion has been proven to be essential for cell survival. Complete loss of 
cell contact with the substratum might lead to apoptosis (anoikis) in normal fibroblasts 
[Meredith et al., 1993], epithelial cells [Stupack et al., 2001] and various cancer cells 
[Marco et al., 2003; Aixinjueluo et al., 2005]. It is believed that attachment to the ECM 
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suppresses the activity of apoptotic factors. Loss of integrin-ECM interaction would 
lead to the activation of apoptotic pathways [Reddig and Juliano, 2005]. 
Besides, integrins are also involved in angiogenesis, which plays a key role in the 
pathological development of malignant cancers. VEGF and bFGF were reported to 
upregulate the expression and activation of several integrins that are involved in 
angiogenesis [Byzova et al., 2000]. Furthermore, several integrins are revealed to be 
essential in modulating angiogenesis using mutant mice and angiogenesis models. For 
example, embryonic deletion of integrin α5β1 induced early mesenchymal 
abnormalities, which affect the ability of endothelial cells to form vessel-like 
structures [Goh et al., 1997].  
2.4.4 Integrin Signaling 
Integrins regulate intracellular signaling pathways that control cytoskeletal 
organization, proliferation, polarity, and motility [Hood and Cheresh, 2002]. Upon 
binding to different components of ECM, integrins activate one or more intracellular 
signaling pathways, which usually involve the phosphorylation of FAK, recruitment of 
adaptor proteins, and subsequent activation of downstream effector molecules. 
Besides, many helper proteins are necessary to integrate the tremendously different 
cues from both inside and outside of cells to modulate the cell behavior as exactly as 
possible. 
2.4.4.1 FAK 
One of the major members of the integrin signaling pathway is the FAK, which 
functions to transmit signals from the ECM into the cytoplasm. FAK is an essential 
 48 
gene product, since the FAK-/- mouse exhibited embryonic lethality [Schlaepfer et al., 
1999]. Many stimuli can induce tyrosine phosphorylation and activation of FAK, 
including growth factors, reagents that stimulate G-protein coupled receptors and 
mechanical stimuli. However, the major mode of regulation of FAK activation is 
through integrin-dependent adhesion to the ECM [Wozniak et al., 2004]. As shown in 
Fig. 2.7, upon integrin-dependent cell adhesion, FAK co-localizes with the integrins at 
focal adhesions, sites of close contact with the ECM, and becomes tyrosine 
phosphorylated and activated. Activated FAK binds to several signaling molecules, 
such as paxillin and vinculin, and promotes cell adhesion and spreading, migration, as 
well as survival and proliferation [Mitra et al., 2005].  
 
Fig. 2.7 Schematic depiction of the signalings leading from integrins to FAK and 
further reactions of the cell. 
 
As shown in Fig. 2.8, FAK contains a FERM domain, a kinase domain and a focal 
adhesion targeting (FAT) domain. The FERM domain mediates interactions of FAK 
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with receptors, such as EGFR and PDGF receptor. The FAT domain associates FAK 
with proteins such as paxillin and talin, which are also involved in integrin-mediated 
signaling. It also links FAK to the activation of Rho GTPases by binding to certain 
GEFs, such as p190 RhoGEF. FAK can be phosphorylated on several tyrosine residues 
(Y397, Y576, Y577, Y861 and Y925), among which Y397 is the major 
autophosphorylation site. After integrin ligand binding and clustering, FAK is 
autophosphorylated at Y397 and recruits Src family kinases to focal adhesions. This 
FAK-Src complex promotes further FAK phosphorylation and activation, as well as 
tyrosine phosphorylation of substrates, such as paxillin and p130Cas, and subsequent 
activation of multiple protein kinase cascades [Wozniak et al., 2004].  
 
Fig. 2.8 FAK domain structure. 
 
2.4.4.2 Other proteins involved in integrin-mediated pathways 
Besides FAK, some other kinases and proteins also play important roles in 
integrin-mediated signaling transduction. For example, integrin-linked kinase (ILK) 
localizes at the sites of integrin connections to the actin cytoskeleton, and has been 
shown to be a critical component of the cell-ECM adhesion structures. ILK binds to 
the cytoplasmic tails of β1 and β3 integrin subunits [Wozniak et al., 2004], as well as a 
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number of proteins, such as CH-ILKBP, and affixin, which form a protein complex 
and bridge the ECM and growth factor receptors to the actin cytoskeleton [Persad and 
Dedhar, 2003]. Consistently, enhanced ILK levels are involved in the progression of 
several tumors, such as prostate, neuroectodermal, and melanoma [Graff et al., 2001; 
Dai et al., 2003].  
Shc is another important protein involved in integrin signaling. It is a group of 
adaptor proteins that are recruited to activated tyrosine kinases in response to ligation 
of integrins α1β1, α5β1, and αvβ3, and to some extracellular receptors in response to 
growth factor stimulation. This might lead to subsequent cell migration, anti-apoptotic 
signaling and cell cycle progression [Wary et al., 1996; Wary et al., 1998]. Constitutive 
phosphorylation of Shc was observed in many highly metastatic cancer cells [Collins 
et al., 1999]. 
2.4.5 Regulation of integrin functions 
In general, integrin-mediated adhesion can be regulated by changing integrin 
affinity for ligand, and/or altering integrin avidity by some affinity-independent 
mechanisms, such as changes in cell shape, and alteration in the diffusion of integrins 
in the plane of the membrane.  
Various stimuli, including growth factors, chemokines, and oncogenes, can trigger 
intracellular signaling pathways that modulate the molecular interactions at the 
integrin cytoplasmic domains [Liddington and Ginsberg, 2002]. These interactions 
may induce the separation of cytoplasmic tails of the α and β chains and probably lead 
to conformational changes in integrin structure, resulting in effective enhancement of 
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integrin affinity for ligand binding [Loftus and Liddington, 1997; Liddington and 
Bankston, 2000].  
Meanwhile, during integrin-ECM interaction, integrins can become clustered at 
focal adhesion sites. Recently a number of reports have shown that lipid rafts play an 
important role in regulating integrin clustering and functioning. As shown in Fig. 2.9, 
lipid rafts are specialized membrane micro-domains rich in cholesterol and 
sphingolipids. Because the lipid bilayer is somewhat thicker in the rafts, certain 
membrane proteins accumulate. Thus lipid rafts can serve as platforms for various 
adaptor and signaling molecules. Lipid raft is implicated in signal transduction events 
induced by adhesion to ECM, which is mediated by integrins [del Pozo et al., 2004; 
Guan, 2004; Palazzo et al., 2004]. It has also been suggested that integrins may 
regulate various cellular events by affecting the positioning of lipid rafts on plasma 
membranes [Guan, 2004; Palazzo et al., 2004]. At the same time, the association of 
integrins with lipid rafts has been documented in a variety of cell types [Yanagisawa et 
al., 2004; Nguyen et al., 2005; Pankov et al., 2005].  
 
(Adopted from Molecular Biology of the Cell, Bruce Alberts et al, 2002.) 
Fig. 2.9 Model of lipid raft in plasma membrane. 
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In addition, as the major component of lipid raft, cholesterol has been demonstrated 
to serve as a modulator of receptor functions [Gimpl et al., 1997]. For example, 
cholesterol levels in the plasma membrane affected both adhesion and signaling 
properties of α5β1 and αvβ3. This was through increasing integrins clustering and 
changing the lateral mobility of other proteins or lipids that interact with integrins 
[Green et al., 1999; Gopalakrishna et al., 2000]. Meanwhile, several reports have 
highlighted the important role of sphingolipids, another major component of lipid raft, 
with integrin receptors. Hidari et al revealed that complete removal of sphingolipids 
from the plasma membrane disrupted cell to substratum adhesion of mouse melanoma 
cells [Hidari et al., 1996]. Recently, a specific glycosphingolipid GM3 was reported to 
bind directly to α5β1 integrin and an increase of membrane cholesterol induced the 
redistribution of GM3-associated α5β1 integrin molecules specifically on the surface 
that is in contact with the substratum [Gopalakrishna et al., 2004]. 
2.5 Objectives of the study 
Metastasis is the most devastating aspect of malignant neoplasms. Although 
advances in surgery, chemotherapy, and radiotherapy have significantly improved the 
treatment of primary malignancies, the occurrence of metastasis still leads to poor 
prognosis and death in patients with malignancy. Therefore metastasis and its process 
should be a major issue to be addressed in cancer research. Many attempts have been 
made to find promising agents against cancer metastasis. Emodin, one of the major 
active components of rhubarb, has been shown to possess a number of anti-tumor 
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activities. However, no systematic study has been carried out on the possible effect of 
emodin against tumor metastasis. Therefore, the objectives of the present study are to 
further investigate the effect of emodin against cell invasion, migration and adhesion 
and the underlying mechanisms involved. The following three steps will be carried out 
to achieve this aim: 
z To study the effects of emodin on cancer cell invasion. MMP-2 and MMP-9, two 
key enzymes involved in invasion process, and related signaling pathways will be 
investigated.  
z To elucidate the pathways involved in the inhibitory effect of emodin on cancer 
cell migration. In this part, the activation of Rac1 and Cdc42, essential molecules 
during cell migration, as well as their signaling will be examined. 








INHIBITORY EFFECT OF EMODIN ON TUMOR CELL INVASION 





Tumor metastasis is the leading cause of deaths in cancer patients [Hanahan and 
Weinberg, 2000]. The process of metastasis consists of a complex cascade of 
interdependent steps, such as intravasation by tumor cells, circulation in lymph and 
blood vessels, arrest at distant vascular bed, extravasation, and proliferation of cells as 
a secondary colony. Cell invasion, the process of translocation of neoplastic cells 
across ECM barriers, is one of essential biological events required for tumor 
metastasis [Bogenrieder and Herlyn, 2003].  
Expression of MMPs has been associated with tumor invasion and metastasis due 
to their ability to proteolytically degrade ECM components such as collagen, 
fibronectin, and laminin [Nabeshima et al., 2002]. MMPs are a large family of 
proteases sharing a diverse range of substrates and currently divided into several 
subgroups: gelatinases, collagenases, stromelysins, stromelysin-like MMPs, 
matrilysins, membrane-type MMPs and other MMPs [Kerkela and Saarialho-Kere, 
2003]. Particularly the gelatinases, MMP-2 and MMP-9, are known to be essential for 
cancer cell invasion as they can degrade type IV, V, and VII collagens, gelatin, and 
some other components of ECM [Kerkela and Saarialho-Kere, 2003]. MMP-2 is 
constitutively present in tissues and mainly regulated at a post-transcriptional level by 
interacting with TIMP-2 [Bernardo and Fridman, 2003]. In contrast, the expression of 
MMP-9 is largely controlled at the transcriptional level and can be stimulated by 
growth factors, cytokines, UV, and TPA [Westermarck and Kahari, 1999].  
Emodin (3-methyl-1, 6, 8-trihydroxyanthraquinone) is an anthraquinone 
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derivative from the rhizome and root of Rheum palmatum, an herb widely used in 
traditional Chinese medicine as a laxative [Shi et al., 2001]. It has been reported that 
emodin possesses a number of biological activities such as vasorelaxative [Huang et 
al., 1991], immunosuppressive [Kuo et al., 2001a], hepatoprotective [Lin et al., 1996], 
and anti-tumor activity [Chang et al., 1996; Shi et al., 2001]. Emodin has been shown 
to be a tyrosine kinase inhibitor that can restrict the activity of HER-2/neu [Zhang et 
al., 1995] and ras-oncogene [Chan et al., 1993], which are involved in the signaling 
pathways of cell proliferation, transformation and differentiation. Recent studies 
suggest that emodin could also induce apoptosis in several kinds of cancer cells [Lee, 
2001a; Jing et al., 2002; Srinivas et al., 2003]. However, so far there is little evidence 
showing the possible effects of emodin on tumor invasion and metastasis. Thus, in 
this part of study, two cancer cell lines with high invasion capacity, a skin squamous 
cancer cell line HSC5 and a breast cancer cell line MDA-MB-231, were used to 
investigate the inhibitory effect of emodin on cell invasion and the possible 
mechanisms involved in its actions.  
3.2 Materials and methods 
3.2.1 Chemicals and reagents 
Emodin, TPA, parthenolide, PD98059, SB203580, and antibody against tubulin 
were purchased from Sigma. SP600125 was from Calbiochem. Antibodies against 
c-Jun, JNK, ERK, p38, phospho-c-Jun, phospho-JNK, phospho-ERK, phospho-p38 
and Histone H1 were obtained from Cell Signaling. Antibodies against MMP-9, IκBα, 
p65 and Sp-1 were provided by Santa Cruz. pAP-1-Luc, pNF-κB-Luc and 
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β-galactosidase plasmid were from Clonetech. 
3.2.2 Cell culture and treatment 
HSC5, derived from human skin squamous cell carcinoma, was kindly provided by 
Dr. S. Kondo (Yamagata University, Yamagata, Japan). MDA-MB-231 (human breast 
cancer cell line) was purchased from ATCC. Both cell lines were cultured in 
monolayers at 37°C, 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 100 μg/ml streptomycin, and 100 
U/ml penicillin. Emodin was dissolved in DMSO as stock solution at 100mM and 
diluted with FBS-free medium to achieve designated concentrations. Same 
concentration of DMSO was always applied to cells as control. 
3.2.3 Cell invasion assay 
To measure the invasion ability of cancer cells, invasion assay was conducted as 
described previously [Albini et al., 1987] with modifications using BD Matrigel® 
invasion chamber. 
(1) Rehydrate the number of Matrigel inserts to be used as directed by 
manufacturer’s manual.  
(2) Cells were pretreated with emodin or other specific inhibitors according to 
the context.  
(3) Cells (2×105 /ml) were inoculated into the culture inserts in the presence or 
absence of 80 nM TPA and various concentrations of emodin or specific inhibitors.  
(4) Incubate the Matrigel invasion chambers for 12 hr in a humidified tissue 
culture incubator, at 37°C, 5% CO2. 
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(5) After incubation, insert a cotton tipped swab into the insert and gently move 
the tip over the membrane surface. 
(6) Repeat the scrubbing with a second swab moistened with medium. 
Scrubbing must be accomplished quickly to avoid drying of the cells adhering to the 
bottom surface of the membrane. 
(7) The lower surfaces of the membrane were fixed with 100% methanol and 
stained with Giemsa solution.  
(8) Cells that had invaded to the lower surface of the membranes were counted 
in five high-power fields (400×) under a microscope.   
3.2.4 Gelatin zymography 
Gelatin zymography was performed essentially as reported earlier with 
modifications [Baba et al., 2000b] to measure the activity of MMP-2 and MMP-9.  
(1) Cells were seeded onto six-well plates in DMEM with 10% FBS and were 
cultured to 80% confluence. 
(2) Cells were then washed and maintained in serum-free medium for 24 hr prior 
to designated treatments with emodin and TPA as indicated in the context. 
(3) The conditioned media were collected after 12 hr and standardized with cell 
number (5×105 cells). 
(4) Mix medium sample with non-reducing sample buffer (62.5 mM Tris-HCl, 
pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue) and let stand for 10 min at 
room temperature. Do not heat. 
(5) Prepare gels (8%) according to the standard procedure. Add 10 mg/ml 
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gelatin stock solution (in H2O; freshly prepared) to the running gel to achieve the 
gelatin concentration of 1 mg/ml. 
(6) Apply samples and run the gel under standard running conditions, at 4°C.  
(7) The resulting gels were washed in renaturing buffer (10 mM Tris, pH 8.0, 
2.5% Triton X-100) with gentle agitation for 30 min at room temperature. 
(8) Decant the renaturing buffer, and replace with developing buffer (50 mM 
Tris-HCl, pH 7.5, 0.2 M NaCl, 10 mM CaCl2, and 1 µM ZnCl2) at 37°C. Equilibrate 
the gel for 30 min at room temperature with gentle agitation and then replace with 
fresh developing buffer and incubate at 37°C for 16 hr. 
(9) Gels were subsequently stained using 0.5% Coomassie blue R-250 in 5% 
(v/v) methanol and 10% (v/v) acetic acid for 1 hr and destained in 10% (v/v) methanol, 
5% (v/v) acetic acid until the bands were seen. 
3.2.5 Western blot 
The changes of the protein expression were detected by western blot. 
(1) Cells were starved in serum-free medium for 24 hr, and then treated as 
designated.  
(2) Cells were collected and washed with ice-cold PBS twice. Cell pellets were 
lysed in lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol) 
supplemented with protease inhibitor cocktail.  
(3) After a brief sonication, lysates were clarified by centrifugation at 20,000 g 
for 15 min at 4°C to remove cell debris. 
(4) The protein content was measured using Bio-Rad Dc protein assay kit.  
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(5) Aliquots of the lysates were subjected to SDS-PAGE gel and electrophoresis 
120 V for 60 min. 
(6) The proteins were transferred to nitrocellulose membrane at 4°C.  
(7) The membrane was blocked in 5% non-fat milk in TBST buffer (10mM 
Tris-HCl, pH 7.5, 100mM NaCl, 0.1% Tween 20) for 1 hr. 
(8) The membrane was then probed with primary antibody overnight at 4°C 
and followed by second antibody. Extensive washes with TBST were applied after 
probed with first and second antibody. 
(9) The signal was visualized using SuperSignal® West Dura Kit, according to 
the manufacturer’s protocol. Densitometric measurements of the bands in western blot 
analysis were performed using digitized scientific software program Kodak 1D 3.5 
purchased from Kodak.  
For detection of MMP-9 protein level in the medium, conditioned medium was 
standardized with cell number and incubated for 2 hr with gelatin-agarose beads to 
achieve 10-fold concentrations of the gelatinases. After recovery by centrifugation, 
beads were washed and resuspended in sample buffer, and heated for 5 min at 100°C 
before being subjected to 8% SDS-PAGE gel. 
3.2.6 Preparation of cytosolic and nuclear extract 
To study the nuclear translocation and transactivation of transcription factors, 
nuclear and cytosolic protein extracts were prepared as described previously with 
modification [Hehner et al., 1998]. 
(1) After designated treatments, cells were harvested and washed twice with 
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ice-cold PBS.  
(2) The pellet was resuspended in cytosolic buffer (10 mM HEPES, pH 7.9, 1.5 
mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml 
aprotinin) on ice for 15 min. 
(3) Nonidet P-40 (final concentration 0.3%) was added into the cell suspension 
and mixed gently. 
(4) The supernatants were collected as cytoplasmic extracts after centrifugation 
with 2,000 g for 10 min.  
(5) The pellets were resuspended with nuclear protein extraction buffer (20 mM 
HEPES, pH 7.9, 0.45 M NaCl, 25% (v/v) glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 
0.5 mM DTT, 0.5 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml aprotinin) and incubated on 
ice for 30 min with gentle agitation.  
(6) The nuclear proteins were collected by centrifugation with 20,000 g at 4°C 
for 15 min.  
(7) Protein concentration was quantified using Bio-Rad protein assay kit. 
3.2.7 Electrophoretic mobility shift assay (EMSA) 
The DNA binding activity of the nuclear protein was performed as described 
previously with modification [Hehner et al., 1998]. In brief:  
(1) NF-κB consensus oligonucleotides (5’-AGTTGAGGGGACTTTCCCAG 
GC-3’) and AP-1 consensus oligonucleotides (5’-CGCTTGATGAGTCGACCGG 
AA-3’) were labeled with T4 kinase and purified through G50 column. 
(2) Equal amounts of nuclear extract (5µg) were mixed with 2 µg of poly(dI-dC), 
 62 
2 µg of bovine serum albumin (BSA), and 100,000 cpm of a 32P-labeled 
oligonucleotide on ice in 5 × binding buffer ( 100 mM HEPES/KOH, pH 7.9, 1 mM 
DTT, 300 mM KCl, and 20% glycerol) in a total volume of 20µl at room temperature 
for 30 min.  
(3) The DNA/protein complex was electrophoresed on a non-denaturing 5% 
polyacrylamide gel using a vertical gel electrophoresis apparatus (Gibco BRL Model 
v16-2) at 150 V for 1.5 hr.  
(4) The gel was dried after electrophoresis and exposed to an x-ray film at 
-80°C. 
3.2.8 Transient transfection and luciferase reporter gene assay 
The transient transfection of pAP-1-Luc, pNF-κB-Luc and pTAL-luc, together 
with β-galactosidase reporter vector were performed in HSC5 cells using 
LipofectamineTM 2000. 
(1) HSC5 cells were subcultured in antibiotics-free medium 24 hr before 
transfection. 
(2) Dilute DNA and lipofectamine 2000 reagent into antibiotics and FBS free 
medium according to the manufacturer’s protocols. 
(3) Mix the diluted DNA and transfection reagent to form DNA-transfection 
reagent complex and incubate for 20 min at room temperature.  
(4) Replace the medium on the cells into fresh antibiotics and FBS-free cell 
culture medium.   
(5) Add the DNA-transfection complex drop-wise into cell culture dish and 
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change medium after 4-6 hr transfection. 
(6) After 18 hr incubation, the cells were treated as designated.  
(7) Cells were then lysed and reporter gene activity was determined with the 
Promega luciferase assay system using LUMI-ONE luminometer. β-Galactosidase 
activity was measured using Promega β-galactosidase enzyme assay system and used 
for normalization of transfection efficiency. 
3.2.9 Statistical Analysis 
Data are presented as means ± standard deviation (SD), and analyzed by Student’s 
t-test. 
3.3 Results 
3.3.1 Suppressive effect of emodin on TPA-induced invasion of HSC5 and 
MDA-MB-231 cells 
To determine whether emodin could inhibit the invasive property of HSC5 cells, 
Transwell plates were used to measure the cell invasion property following TPA 
stimulation. As shown in Fig. 3.1, emodin inhibited the invasiveness of TPA-treated 
HSC5 cells through Matrigel®-coated membrane in a concentration-dependent 
manner. To rule out the possibility that such inhibition is due to its cytotoxicity, the cell 
viability of emodin–treated cells was determined using MTT assay. The result showed 
that emodin had no significant effect on cell viability at concentration ranging from 
10-40 μM within 12 hr treatment (data not shown), suggesting that emodin inhibits 
cell invasion without obvious cellular cytotoxicity. The inhibitory effect of emodin 
was also conducted on MDA-MB-231, a breast cancer cell line with high invasive 
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capacity. Similar dose-response inhibitory effect was observed in this cell line (Fig. 





















Fig. 3.1 Effects of emodin on TPA-induced invasiveness of HSC5 cells. (A) 
Inhibitory effect of emodin on invasiveness of HSC5 cells. After pretreatment with 0-40 
μM emodin for 2 hr, cells (2×105 /ml) were seeded onto Matrigel®-coated membranes of 
Transwell plates, followed by incubation with 80 nM TPA for additional 12 hr. The lower 
surfaces of the membranes from the transwell units were fixed with 100% methanol and 
stained with Giemsa solution. Cells that had invaded to the lower surface of the 
membranes were counted under a light microscope. Data are presented as means ± SD. 
All experiments were done in triplicate. (* p<0.05 compared to the TPA group and 




























 Fig. 3.2 Effects of emodin on TPA-induced invasiveness of MDA-MB-231 cells. 
Cell invasion assay was conducted in the same way as Fig. 3.1, except for 0-20 μM 
emodin pretreatment. Data are presented as means ± SD. All experiments were done in 
triplicate. (* p<0.05 compared to the TPA group and analyzed by Student’s t-test).  
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3.3.2 Inhibition of TPA-induced MMP-9 activity and expression by emodin 
MMP-9 and MMP-2 are the key enzymes in the degradation of type IV collagen, 
which acts as the “backbone” of cellular basement membranes [Nabeshima et al., 
2002]. Gelatin zymography was performed to examine the activities of MMP-9 and 
MMP-2 using conditioned medium, which was collected and measured after 12 hr 
TPA stimulation with or without emodin pretreatment. Both MMP-2 and MMP-9 were 
detected in the conditioned media of HSC5 cells (Fig. 3.3A), while TPA significantly 
increased the MMP-9 activity. Emodin pretreatment inhibited MMP-9 activity in a 
concentration-dependent manner. At 40 μM, emodin reduced MMP-9 activity to the 
basal level. In contrast, the activity of MMP-2 was not significantly affected by 
emodin, or by TPA.  
In order to determine whether the down-regulation of MMP-9 activity was due to 
decreased expression of MMP-9, the level of MMP-9 protein in the conditioned 
medium secreted by HSC5 cells was measured. The result showed that emodin 
inhibited the TPA-induced expression of MMP-9 in a concentration-dependent 
manner (Fig. 3.3B). At 40 μM, emodin suppressed the MMP-9 expression to the basal 
level. Similar inhibitory effect was also observed on MDA-MB-231 cells (data not 
shown). Meanwhile, the level of MMP-9 proteins in cell lysates was measured and 
found similar inhibitory effect of emodin on TPA-induced MMP-9 expression (Fig. 
3.3C). Take together, these results suggest that emodin might suppress cell invasion 












Fig. 3.3 Effects of emodin on TPA-induced activity and expression of MMP-9 and 
MMP-2.  (A) Concentration–dependent decrease of TPA-induced MMP-9 activity 
after emodin treatment. HSC5 cells were incubated with 80 nM TPA for 12 hr after 2 hr 
pretreatment of 0-40 µM emodin. Conditioned media were harvested and cells were 
counted. Aliquots of conditioned medium normalized for differences of cell number 
were subjected to gelatin zymography. (B) Western blot analysis of TPA-induced 
MMP-9 expression in 10× concentrated conditioned medium. Cell treatment, 
conditioned medium collection and normalization are the same as for Fig. 3.3A. 
Western blot was conducted as described in Materials and Methods. (C) Western blot 
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3.3.3 Suppressive effect of emodin on AP-1 signaling pathways 
Transcriptional regulation plays an important role in the expression of MMPs, and 
AP-1 is a major transcription factor that regulates MMP-9 expression [Westermarck 
and Kahari, 1999]. The transcriptional activity of AP-1 by transient transfection with 
an AP-1 luciferase construct was measured. As shown in Fig. 3.4, TPA significantly 
stimulated the transcriptional activity of AP-1 and emodin efficiently inhibited the 
TPA-induced AP-1 luciferase activity in HSC5 cells. SP600125, a chemical 
specifically inhibiting JNK activity and subsequent AP-1 activation, was used as a 
positive control. These data suggest that AP-1 is likely to be involved in the inhibitory 
effect of emodin on TPA-induced MMP-9 expression. 
To understand the possible mechanisms involved, the effect of emodin on the 
DNA-binding activity of AP-1 was further examined using EMSA. TPA significantly 
increased DNA binding activity of AP-1, and emodin inhibited the binding activity in a 
concentration-dependent pattern (Fig. 3.5), being consistent with the effects of emodin 
on the transcriptional activity of AP-1 (Fig. 3.4). No obvious change of AP-1 
DNA-binding activity was observed in the cells treated with emodin alone. 
c-Jun is one of the main components of transcription factor AP-1, and also, serves 
as the target for ERK, JNK and p38 kinase [Karin, 1995; Bode and Dong, 2000]. It is 
well known that c-Jun phosphorylation is essential for the binding and transcriptional 
activation at TPA-responsive element, which is bound by AP-1 [Karin, 1995; Bode 
and Dong, 2000]. Therefore, the phosphorylation level of c-Jun was tested after 
emodin treatment. The result indicates that TPA markedly enhanced c-Jun 
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phosphorylation, and emodin significantly impaired c-Jun phosphorylation in a 

































Fig. 3.4 Effects of emodin on TPA-induced transcriptional activity of AP-1. 
pAP-1-Luc was transfected into HSC5 cells together with β-gal as normalization of 
transfection efficiency. HSC5 cells were incubated with 80 nM TPA for 6 hr after 2 hr 
pretreatment of 40 µM emodin or 20µM SP600125. Data are presented as means ± SD of 
three independent experiments and expressed as percentage. (* p<0.05 compared to the 














Fig. 3.5 Effects of emodin on TPA-induced AP-1 binding activity. Cells were 
pretreated with 0-40 μM emodin for 2 hr, followed by 2 hr TPA stimulation. The nuclear 
extract was subjected to EMSA as described in Materials and Methods. Cold probe, 
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Fig. 3.6 Effects of emodin on TPA-induced c-Jun phosphorylation. Cells were 
pretreated with 0-40 μM emodin for 2 hr. The cells were subsequently stimulated with 80 
nM TPA for another 2 hr. Total cell lysate protein of 40 μg was subjected on 10% 
SDS-PAGE. Western blot was done as described in Materials and methods.   
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3.3.4 Inhibitory effect of emodin on the phosphorylation of JNK and ERK, but 
not p38 
The MAPK pathways can influence AP-1 transactivation by increasing the level of 
AP-1 components or altering the phosphorylation of their subunits such as c-Jun 
[Karin, 1995; Bode and Dong, 2000]. To determine which class of MAPK is involved 
in emodin-mediated inhibition of AP-1 transactivation, the effect of emodin on the 
phosphorylation and activation of ERK, JNK and p38 kinase was examined. The 
preliminary data showed that phosphorylation of MAPK occurred at 1-3 hr after TPA 
treatment in HSC5 cells (data not shown). Thus, the effect of emodin on JNK, ERK, 
and p38 phosphorylation was investigated in cells stimulated by 80 nM TPA for 2 hr. 
PD98059 (a specific ERK inhibitor), SP600125 (a specific JNK inhibitor) and 
SB203580 (a specific p38 inhibitor) were used as respective positive controls. As 
shown in Fig. 3.7, emodin inhibited TPA-induced ERK and JNK phosphorylation in a 
concentration-dependent manner, while having no evident effect on phosphorylation 
of p38 (Fig. 3.8). Total protein level of ERK, JNK and p38 did not change with TPA 
and/or emodin treatment. These results suggest that inhibition of ERK and JNK 
phosphorylation by emodin might be one of the underlying mechanisms involved in its 










Fig. 3.7 Emodin, as well as ERK and JNK inhibitors, suppressed TPA-induced ERK 
and JNK phosphorylation. HSC5 cells were pretreated with 0-40 μM emodin, 40 μM 
PD98059, or 20 μM SP600125 for 2 hr. Cells were then stimulated with 80 nM TPA for 
another 2 hr. Western blot of whole cell lysates was performed as described in Materials 
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Fig. 3.8 Emodin showed no effect on TPA-induced p38 phosphorylation. HSC5 cells 
were pretreated with 0-40 μM emodin or 10 μM SB203580 for 2 hr. Cells were then 
stimulated with 80 nM TPA for another 2 hr. Western blot of whole cell lysates was 
performed as described in Materials and Methods.   
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3.3.5 Inhibitory Effect of emodin on NF-κB signaling pathway  
NF-κB is another major transcription factor that regulates MMP-9 expression 
[Westermarck and Kahari, 1999]. Here the transcriptional activity of NF-κB was 
tested using a NF-κB luciferase reporter plasmid. The result in Fig. 3.9 showed that 
TPA significantly stimulated the NF-κB transactivation; whereas, emodin significantly 
inhibited TPA-induced luciferase activity. Parthenolide, an inhibitor targeting on IKK 
complex, was used as a positive control. These data, together with the results from Fig. 
3.3, suggest the possible involvement of NF-κB in the inhibitory effect of emodin on 
TPA-induced MMP-9. 
To further determine the molecular mechanism involved in emodin-mediated 
suppression on NF-κB transactivation, the effect of emodin on the DNA-binding 
activity of NF-κB was tested. EMSA result revealed that TPA caused significant 
increase of NF-κB DNA binding, and emodin inhibited NF-κB DNA binding in a 
concentration-dependent fashion, being consistent with the effect of emodin on the 
transcriptional activity of NF-κB (Fig. 3.10). No obvious change of NF-κB 
DNA-binding activity was observed in the cells treated with emodin alone. 
It is well known that TPA activates NF-κB via IκBα phosphorylation and 
degradation, followed by p65 nuclear translocation [Ghosh and Baltimore, 1990; 
Henkel et al., 1993]. Thus, the effect of emodin on the degradation of IκBα and 
nuclear translocation of p65 was tested in TPA-stimulated cells. As shown in Fig. 3.11, 
TPA treatment caused significant decrease of IκBα at 30 min and 45 min. This 
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reduction was associated with an increasing translocation of p65 into the nucleus. 
Pretreatment of the cells with 40 μM emodin for 2 hr significantly inhibited both IκBα 
degradation and p65 nuclear translocation. Treatment of cells with emodin alone had 
no effect on IκBα level (data not shown). The reduced IκBα degradation and p65 
nuclear translocation are thus found to be consistent with the reduced NF-κB DNA 
































Fig. 3.9 Effects of emodin on TPA-induced transcriptional activity of NF-κB. 
pNF-κB-Luc was transfected into HSC5 cells together with β-gal as normalization of 
transfection efficiency. After 2 hr pretreatment with or without 40 μM emodin or 5 μM 
parthenolide, the cells were cultured with 80 nM TPA for additional 6 hr. Luciferase 
activity was measured as described in Materials and Methods. Data are presented as 
means ± SD of three independent experiments and expressed as percentage. (* p<0.05 









Fig. 3.10 Emodin dose-dependently inhibited TPA-induced NF-κB binding activity. 
Cells were pretreated with or without 0-40 μM emodin for 2 hr, followed by TPA 
stimulation for 1 hr. The nuclear extract was subjected to EMSA as described in 
Materials and Methods. Cold probe, unlabeled oligonucleotides for NF-κB. Sp-1 is 
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3.3.6 Inhibition of TPA-induced MMP-9 activity and cell invasion by ERK 
Inhibitor, JNK Inhibitor and NF-κB Inhibitor  
To further elucidate the involvement of ERK, JNK and NF-κB in the inhibitory 
effect of emodin on cancer cell invasion, the effects of their specific inhibitors on cell 
invasion and MMP-9 production were investigated to mimic the actions of emodin in 
HSC5 cells. The cells were incubated with TPA for 12 hr after 2 hr pretreatment of 
emodin, PD98059, SP600125, or parthenolide (a known NF-κB inhibitor) [Hehner et 
al., 1999] respectively. Cell invasion assay and gelatin zymography data showed that 
these compounds inhibited invasion and MMP-9 activity of HSC5 cells, similar to the 
effect of emodin (Fig. 3.12 and 3.13). Therefore, it is believed that ERK, JNK and 
NF-κB are involved in the up-regulation of MMP-9 and cell invasion in TPA-treated 












Fig. 3.11 Effects of emodin on IκBα degradation and p65 nuclear translocation. Cells 
were pretreated with 40 μM emodin for 2 hr and then stimulated with 80 nM TPA up to 1 
hr. Cytosolic and nuclear proteins were prepared and analyzed by Western blot. Tubulin 
and histone H1 serve as cytosolic and nuclear loading control, respectively. 
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Fig. 3.12 Effects of emodin, SP600125, PD98059 and parthenolide on TPA-induced 
MMP-9 production. HSC5 cells were stimulated for 12 hr with 80 nM TPA after 2 hr 
pretreatment of 40 μM emodin, 20 μM SP600125, 40 μM PD98059, or 10 μM 











































Fig. 3.13 Effects of emodin, SP600125, PD98059 and parthenolide on TPA-induced 
cell invasion. HSC5 cells were stimulated for 12 hr with 80 nM TPA after 2 hr 
pretreatment of 40 μM emodin, 20 μM SP600125, 40 μM PD98059, or 10 μM 
parthenolide respectively. Invasion assay was done as described in Materials and 
methods. Invasion data are presented as means ± SD of three independent experiments 
and expressed as percentage. (* p<0.05 compared to the TPA group and analyzed by 




In this study, the effect of emodin against cancer cell invasion and the mechanisms 
involved was investigated. Nontoxic levels of emodin could efficiently suppress the 
invasiveness of TPA-treated cancer cells (Fig. 3.1 and 3.2) by decreasing the activity 
and production of MMP-9 through inhibiting AP-1 and NF-κB signaling pathways.  
MMPs play important roles in the degradation of ECM to allow tumor invasion 
and metastasis [Nabeshima et al., 2002]. Among various human MMPs reported 
previously, MMP-9 can digest type IV collagen, the “backbone” of basement 
membrane, and is regarded as a metastatic marker in transformed cell lines 
[Nabeshima et al., 2002]. Consistent with some previous reports on the inhibition of 
MMP-9 and suppression of invasiveness and metastasis of cancer cells using various 
chemopreventive agents [Shao et al., 1998; Alhasan et al., 2001; Abiru et al., 2002; Ho 
et al., 2002], in the present study emodin has been shown to inhibit TPA-induced 
MMP-9 expression and activity in a dose-dependent fashion (Fig. 3.3). The inhibitory 
effect of emodin on MMP-9 expression provides convincing explanation for its 
suppression of invasiveness of HSC5 cells observed in the cell invasion assay (Fig. 
3.1). Similar suppressive effect of emodin was also observed in MDA-MB-231 breast 
cancer cells (Fig. 3.2), suggesting that emodin-mediated decrease of MMP-9 
expression and cell invasiveness is also effective in other types of cancer cells. 
The expression of MMP-9 is largely controlled at the transcriptional level 
[Westermarck and Kahari, 1999]. In the promoter region of MMP-9 gene there are two 
AP-1 binding sites and one NF-κB binding site [Sato and Seiki, 1993]. Mutations in 
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AP-1 and NF-κB binding sites can reduce or even abolish the induction of MMP-9 by 
TPA in rat mesangial cells [Yokoo and Kitamura, 1996]. In this study, emodin 
markedly suppressed the TPA-induced AP-1 DNA-binding (Fig. 3.5) and 
transcriptional activity (Fig. 3.4). Besides, emodin inhibited TPA-induced 
phosphorylation of c-Jun in a concentration-dependent manner (Fig. 3.6). Since the 
activity of AP-1 can be modulated through the phosphorylation of c-Jun [Karin et al., 
1997], a major component of AP-1, it is thus believed that the inhibitory effect of 
emodin on AP-1 DNA binding activity and transcriptional activation could be through 
suppressing the phosphorylation of c-Jun. 
It is well established that c-Jun phosphorylation is mediated by MAPK pathways 
[Karin, 1995]. Generally there are three classes of MAPKs: ERK, JNK, and p38 
MAPKs. Activation of MAPK occurs through phosphorylation of specific threonine 
and tyrosine, and the components of AP-1, such as c-Jun, can be phosphorylated after 
the translocation of activated MAPKs to the nucleus [Cowley et al., 1994]. Emodin has 
been shown to inhibit the phosphorylation of JNK and ERK, but not p38 (Fig. 3.7 and 
3.8). Since c-Jun is the phosphorylation target of both JNK and ERK [Bode and Dong, 
2000], it is likely that emodin inhibits the phosphorylation of c-Jun through 
suppressing JNK and ERK activation. It has been shown previously that activation of 
JNK and/or ERK can induce cancer invasion through c-Jun and AP-1 signaling 
pathway [Lakka et al., 2000; Shin et al., 2002]. Some chemopreventive agents, such as 
aspirin and penta-O-galloyl-β-D-glucose, can inhibit cancer cell invasion and AP-1 
transactivation through suppressing JNK and/or ERK activation [Abiru et al., 2002; 
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Ho et al., 2002]. In this study, SP600125, a specific JNK inhibitor and PD98059, a 
specific ERK inhibitor, both effectively inhibited TPA-induced phosphorylation of 
ERK and JNK (Fig. 3.7), MMP-9 expression (Fig. 3.12) and cell invasion (Fig. 3.13), 
thus confirming that the inhibition of ERK and JNK cascades is critical in diminishing 
TPA-induced cell invasion. Therefore, it is believed that emodin may suppress 
TPA-induced MMP-9 expression and cancer cell invasion through JNK and ERK 
pathways.  
At present, it is still not clear how emodin affects MAPK signaling pathways. 
Several studies have demonstrated that TPA can activate the GTP-binding protein Ras 
that plays an important role in regulating the MMP-9 expression [Thomas et al., 1992; 
Sato et al., 2000; Moon et al., 2003].  Not only the classical Raf/MEK1/2/ERK1/2 
mitogenic cascade but also the p38 and JNK signaling cascades can be activated by 
TPA in a ras-dependent fashion [Okumura et al., 1999; Baba et al., 2000a]. Since 
emodin has been shown to display highly selective activity against ras-oncogene 
[Chang et al., 1996], it is possible that this suppression leads to inhibition of 
TPA-induced ERK1/2 and JNK phosphorylation, followed by inhibition of MMP-9 
expression and reduced invasiveness in TPA-stimulated cells.  
On the other hand, NF-κB is another nuclear transcription factor that is known to 
be important in the regulation of MMP-9 expression [Sato and Seiki, 1993]. NF-κB, 
one of the main molecular targets of chemopreventive phytochemicals [Surh et al., 
2001], is a transcription factor involved in multiple cellular processes, including 
cytokine gene expression, cellular adhesion, apoptosis and metastasis [Bharti and 
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Aggarwal, 2002]. In unstimulated cells, NF-κB is generally sequestered in the 
cytoplasm by the IκB proteins. When stimulated, IκB is phosphorylated and degraded. 
NF-κB, released from the inhibitors, translocates from cytoplasm into the nucleus, 
binds to the promoter region of genes containing its specific sites and activates gene 
transcription [Bharti and Aggarwal, 2002]. In this study emodin has been 
demonstrated to suppress TPA-mediated IκBα degradation and p65 nuclear 
translocation (Fig. 3.11), thus inhibiting TPA-induced NF-κB DNA binding (Fig. 3.10) 
and transcriptional activation (Fig. 3.9). It has been reported earlier that emodin 
inhibited TNF-induced NF-κB activation in human vascular endothelial cells [Kumar 
et al., 1998]. Therefore, it appears that emodin is capable of acting against NF-κB 
activation in various cell types and with different stimuli. Besides, nontoxic level of 
parthenolide, a specific inhibitor of NF-κB signaling pathway, inhibited cell invasion 
(Fig. 3.13) and MMP-9 expression (Fig. 3.12), suggesting that NF-κB pathway is 
involved in the invasion and metastasis of TPA-stimulated cancer cells; and NF-κB 
serves as one of the molecular targets for emodin in its effect against cancer invasion.    
Taken together, in this part of the study, emodin has been shown to inhibit 
TPA-induced cell invasiveness and MMP-9 expression in human cancer cells through 
suppressing both AP-1 and NF-κB signaling pathways. Such findings suggest that 




















EMODIN INHIBITS TUMOR CELL MIGRATION THROUGH 





Cell migration is an integral cellular response to extracellular stimuli, and a 
defining feature of tumor metastasis [Friedl and Wolf, 2003]. Thus, much effort to 
reduce the spread of malignant tumors has been recently focused on cell migration. 
Many growth factors can produce some of the key features of cell motility. Among 
them, EGF has been shown to stimulate the migration of both normal and tumor cells, 
including normal epithelial cells, fibroblasts, renal and breast carcinoma cells 
[Matthay et al., 1993; Price et al., 1996; Turner et al., 1996; Sturge et al., 2002].  
Although a complex molecular interplay has been reported for the underlying 
mechanism of cell migration, several lines of evidence have recently suggested the 
possible involvement of PI3K signaling pathway in the cell motility process [Derman 
et al., 1997; Krasilnikov, 2000; Sotsios and Ward, 2000]. PI3K signaling has been 
shown to be activated by various growth factors, such as insulin, interleukins, and EGF. 
Selective activation of PI3K using constitutively active PI3K mutants can promote cell 
migration [Reif et al., 1996; Derman et al., 1997] and inhibition of PI3K signaling 
interfered with cell migration [Pilkington et al., 1998; Sotsios and Ward, 2000].   
The results from Chapter 3 have demonstrated that emodin exhibits strong 
anti-invasion activity in cancer cell lines. Since cell migration is another critical 
component of cancer cell metastasis, in this part of study, the effect of emodin on 




4.2 Materials and Methods 
4.2.1 Cell lines 
MDA-MB-231 (a human breast cancer cell line) and HepG2 (a human 
hepatocarcinoma cell line) were purchased from ATCC (Manassas, VA). HSC5, 
derived from human skin squamous carcinoma, was kindly provided by Dr. S. Kondo 
(Yamagata University, Yamagata, Japan). MDA-MB-231 and HSC5 cells were 
cultured in DMEM supplemented with 10% FBS. HepG2 cells were grown and 
passaged in MEM containing 10% FBS.  
4.2.2 Chemicals and reagents 
Emodin and FITC-conjugated phalloidin were purchased from Sigma (St. Louis, 
MO). LY294002 (a specific PI3K inhibitor), antibody against phospho-Akt (Ser473), 
phospho-Akt (Thr308) and Akt were obtained from Cell Signaling (Beverly, MA). 
Antibody against PAK1 was purchased from Santa Cruz Technology (Santa Cruz, 
CA). Sepharose 4B was from Amersham Bioscience (Uppsala, Sweden). The 
Cdc42/Rac1 activation kit was from Upstate (Lake Placid, NY). Recombinant human 
EGF was from Calbiochem (San Diego, CA).   
4.2.3 Plasmids and transfection 
Vectors expressing dominant-negative (DN)-Cdc42 and constitutively active 
(CA)-Cdc42 were gifts from Dr. A Hall (University College London, London, UK).  
DN-Rac1 and CA-Rac1 vectors were from Dr. JT Parsons (University of Virginia). 
The DN-p110 and CA-p110 plasmids were kindly provided by Dr. C Huang (New 
York University). An expression vector for red-fluorescent protein (pDsRed) was 
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from Clonetech (Palo Alto, Calif.). Transient transfection was performed in 
MDA-MB-231 cells using Lipofectamine® 2000 reagent according to the 
manufacturer’s protocol. All transfections were normalized for total DNA using 
vector plasmid. 
4.2.4 Cell migration assay 
Migration assay was conducted as described previously [Albini et al., 1987] with 
modifications using BD Falcon® 8.0-µm Cell Culture Inserts (Becton Dickinson, 
Franklin Lakes, N.J.).  
(1) Membrane of cell culture inserts was coated with purified fibronectin at a 
concentration of 5 μg/ml.  
(2) After starvation in serum-free medium for 24 hr, cells were collected using 
cell dissociation buffer and resuspended in serum-free medium containing 0.1% 
BSA. 
(3) Cells were pretreated with emodin (0-40μM) or 10 μM LY294002 for 1 hr.  
(4) Cells (4×105/ml) were seeded into transwell chambers in the presence or 
absence of 20 ng/ml EGF and various concentrations of emodin or LY294002.  
(5) After 4 hr incubation, the lower surfaces of the membrane were fixed with 
100% methanol and stained with 0.5% crystal violet solution.  
(6) Cells that had migrated to the lower surface of the membranes were counted 
in five high-power fields under an inverted microscope.  
For migration assay of transiently transfected cells, pDsRed plasmid was used to 
mark the transfected cells. As described above, cells were transiently transfected with 
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various plasmids, serum starved, trypsinized, and resuspended in BSA containing 
medium. After normalization by counting pDsRed positive cells (with red 
fluorescence) under a fluorescence microscope, cells (2×105 transfected cells/ml) 
were pretreated according to the context and subjected to transwell chambers. Only 
pDsRed positive cells that migrated through the membrane after 4 hr incubation were 
counted by fluorescence microscopy. The data were presented relative to cells 
transfected with empty vector and stimulated with EGF, which was normalized to 
100%.    
4.2.5 Immunofluorescence 
Cell cytoskeletal changes were tested using immunofluorescence method. 
(1) Cells were first seeded on fibronectin-coated coverslips at a density of 
2.5×103 cells /coverslip and then serum starved for 24 hr.  
(2) After various designated treatment, cells were fixed in 2% 
paraformaldehyde in PBS for 1 hr in room temperature.  
(3) Cells were permeabilised with 0.5% Triton X-100 in PBS, and then blocked 
in blocking solution (1% BSA, 0.2% Tween-20 in PBS) for 1 hr. 
(4) Cells were further incubated with 500ng/ml FITC-conjugated phalloidin for 
1 hr at room temperature.  
(5) After extensive wash with washing buffer (0.2% Tween-20 in PBS), 
coverslips were mounted onto slides using SlowFade® light anti-fade kit (Molecular 
Probes, Eugene, Oregon). 
(6) Cells were visualized under a fluorescence microscope (Nikon, Tokyo, 
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Japan) and photographed. Cytoskeletal features were quantified in fields of view 
blindly selected at random.  
4.2.6 Western blot 
The experiment procedures for western blot were described in detail in chapter 3 
with slight modifications. In brief, cells were starved in serum-free medium for 24 
hr, and then treated as designated. Cell pellets were lysed in lysis buffer (50mM 
Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150mM NaCl, 1 mM 
EGTA, 1mM PMSF, 1mM Na3O4, 1mM NaF) with proteinase inhibitor cocktail 
(Roche). Aliquots of the lysates were subjected to 10% SDS-PAGE and transferred 
to nitrocellulose membrane. The membrane was probed with primary antibody 
followed by second antibody and visualized using SuperSignal® West Dura kit 
(Pierce, Rockford, IL), according to the manufacturer’s protocol.  
4.2.7 Co-Immunoprecipitation Assay 
The protein-protein interaction between PAK1 and Cdc42 or Rac1 was studied 
using protein co-immunoprecipitation assay. 
(1) After designated treatment, whole cell lysates were prepared with 
co-immunoprecipitation lysis buffer (50mM HEPES, pH 7.6, 250 mM NaCl, 0.1% 
NP-40, 5mM EDTA, 0.5mM PMSF and the proteinase inhibitor cocktail). 
(2) Protein concentration was determined by Bio-Rad DC protein assay 
(Bio-Rad, Hercules, Calif.).  
(3) 500 µg of cell lysates were incubated with 2µg of PAK1 antibody for 1 hr at 
4°C.  
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(4) Protein-antibody complexes were collected after incubation with protein 
A-Sepharose beads for 1 hr at 4°C.  
(5) The beads were washed with ice-cold co-immunoprecipitation lysis buffer 
three times. 
(6) After boiling in SDS sample buffer (62.5mM Tris-HCl, pH 6.8, 2% SDS, 
10% glycerol, 50 mM DTT, 0.01% bromophenol blue), samples were resolved by 
SDS-PAGE, and immunoblotted with antibody against Cdc42 or Rac1.  
4.2.8 Cdc42 and Rac1 activation assay 
Cdc42 and Rac1 activation assay was analyzed using an activation assay kit from 
Upstate (Lake Placid, N.Y.). In brief: 
(1) After designated treatment, cells were lysed with 1×Mg2+ lysis/washing 
buffer. 
(2) 10μl of GST–PAK1 p21-binding domain (PBD) agarose beads was added to 
0.5 ml cell lysate and incubated at 4°C for 60 min.  
(3) The agarose beads were collected and washed three times with washing 
buffer, resuspended in SDS sample buffer (62.5mM Tris-HCl, pH 6.8, 2% SDS, 10% 
glycerol, 50 mM DTT, 0.01% bromophenol blue) and boiled for 5 min.  
(4) The samples were subjected on SDS-PAGE and immunoblotted with 
antibody against Cdc42 or Rac1. 
4.2.9 Statistics 




4.3.1 Emodin inhibited EGF-induced migration in human cancer cells  
The results in Chapter 3 have demonstrated the strong anti-invasion activity of 
emodin in some cancer cell lines. Since cell migration is another critical step in 
metastatic process, the effect of emodin on cancer cell migration was further 
investigated. Here, the effect of emodin on EGF-stimulated cell migration was 
measured in human breast cancer MDA-MB-231 cells. As shown in Fig. 4.1A, 
emodin treatment alone did not significantly affect cell migration, while it 
completely suppressed EGF-stimulated cell motility in MDA-MB-231 cells. To 
confirm that such inhibition is not cell-type specific, the effect of emodin on cell 
migration was also tested using other cancer cells, including HSC5 and HepG2. As 
shown in Fig. 4.1B, emodin showed a similar inhibitory effect in both HSC5 and 
HepG2 cells.  
To rule out the possibility that such inhibition is due to its cytotoxicity, the cell 
viability of emodin–treated cells was determined using MTT assay. The result 
showed that emodin had no significant effect on cell viability at concentration 
ranging from 10-40 μM up to 12hrs of treatment (data not shown), suggesting that 
































Fig. 4.1 Effects of emodin on EGF-induced cell migration. Cells were incubated 
with 20 ng/ml EGF for 4 hr after pretreated with 0-40 μM emodin for 1 hr. Cells that 
migrated to the lower surface of the membrane were fixed, stained and counted, as 
described in Materials and Methods. (A) Representative images showing the 
inhibitory effect of emodin on migration of MDA-MB-231 cells. (B) Quantification of 
the inhibitory effect of emodin on migration of MDA-MB-231, HSC5, and HepG2 
cells. Migration data are presented as means ± SD of three independent experiments 




























4.3.2 Emodin blocked EGF-induced PI3K activation 
The PI3K signaling pathway promotes cell migration leading to cancer cell 
metastasis [Krasilnikov, 2000; West et al., 2002]. PI3K is a heterodimer composed of 
two subunits, a p85 regulatory subunit and a 110-kDa catalytic subunit [Krasilnikov, 
2000]. In this study, PI3K was confirmed  to be required for EGF-induced 
migratory response in MDA-MB-231 cells. As shown in Fig. 4.2, cells 
overexpressing DN mutants of PI3K, DN-p110, failed to respond to EGF treatment 
in the cell migration assay. Furthermore, DN-p110 overexpression suppressed the 
EGF-induced formation of filopodia and lamellipodia, two main cytoskeleton 
changes that are known to play an important role in the onset and maintenance of cell 
migration (Fig. 4.3) [Pawlak and Helfman, 2001]. These data suggest a pivotal PI3K 
involvement in EGF-induced cell migration. 
Thus, the next step is to examine whether emodin inhibits EGF-stimulated cancer 
cell migration via the PI3K pathway. One well-defined downstream effector of PI3K 
is Akt [Krasilnikov, 2000]. As activation of PI3K correlated well with 
phosphorylation at Thr308 and Ser473 residues of Akt [Chan et al., 1999], the effect 
of emodin on the phosphorylation of Akt was investigated. As shown in Fig. 4.4, 
emodin markedly decreased the EGF-induced phosphorylation of Akt, which was 
also abolished by LY294002, in a concentration-dependent manner. Emodin or 
LY294002 alone did not affect the phosphorylation of Akt. Consistently, both 
emodin and LY294002 suppressed the EGF-induced cell migration (Fig. 4.5). 
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Emodin and LY294002 also showed similar inhibitory effect on EGF-induced 
migration in two other cell lines, HSC5 and HepG2 (data not shown). These data 
suggested that emodin might suppress EGF-induced cell migration by interfering 

























Fig. 4.2 Effects of overexpression of DN-p110 on EGF-induced cell migration. 
MDA-MB-231 cells were transfected with empty vector, DN-p110, together with 
pDsRed (a red fluorescence protein) expression vector used to mark the transfected cells. 
Cells were subjected to cell migration assay as described in Materials and Methods, in 
the absence (open columns) or presence (solid columns) of 20 ng/ml EGF. Transfected 
cells (with red fluorescence) that had migrated to the lower surface of the membranes 







Fig. 4.3 Effects of overexpression of DN-p110 on EGF-induced actin cytoskeleton 
changes. After transfection with empty vector or DN-p110, together with pDsRed, 
cells were incubated with or without EGF for 30 min. Then cells were fixed and 
stained with FITC-conjugated phalloidin for detecting cytoskeleton changes. Arrows 














Fig. 4.4 Effects of emodin and LY294002 on EGF-induced phosphorylation of Akt. 
MDA-MB-231 cells were pretreated with 0-40 μM emodin or 10 μM LY294002 for 1 hr, 
followed by 15 min EGF incubation. Western blot of whole cell lysates was performed as 











































Fig. 4.5 Effects of emodin and LY294002 on EGF-induced cell migration. Cells were 
stimulated for 4 hr with EGF after 1 hr pretreatment with 40 μM emodin or 10 μM 
LY294002. A migration assay was performed as described in Materials and methods. Data 
are presented as means ± SD of three independent experiments and expressed as percentage. 






















4.3.3 Involvement of the PI3K signaling pathway in emodin’s effect against 
cell migration  
To further confirm the involvement of PI3K in the inhibitory effect of emodin on 
EGF-induced cell migration, the cell migration after transfection with CA-p110 was 
measured. As shown in Fig. 4.6 and 4.7, overexpression of CA-p110 alone 
significantly enhanced cell migration and EGF was unable to further increase cell 
migration in those cells. Emodin, as well as LY294002, clearly inhibited the 
migration of CA-p110-overexpressing cells with or without EGF. Together with the 
results in Fig. 4.4 and 4.5, these findings clearly suggested that emodin suppressed 
cell migration by interfering with the PI3K signaling pathway.  
4.3.4 Inhibitory effect of emodin on EGF-induced actin cytoskeleton changes 
and Cdc42/Rac1 activation  
Certain cytoskeletal changes, such as filopodia and lamellipodia, are closely 
related to cell migration [Schmitz et al., 2000; Price and Collard, 2001]. To further 
confirm that emodin suppresses cell migration through PI3K-dependent pathway, the 
cytoskeleton changes were measured using an immunofluorescence method. As 
shown in Fig. 4.8, EGF induced a significant increase in filopodia and lamellipodia 
formation; 49% and 63% of cells formed filopodia and lamellipodia, respectively, 
after 30 minutes of EGF stimulation. With emodin treatment, the number of cells 
with filopodia extensions was decreased to 23%, and that with lamellipodia 
extensions was decreased to 29%. A similar inhibitory effect was also observed with 
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LY294002. Taken together, these results further support the notion that emodin 
inhibits an EGF-induced PI3K-dependent pathway, leading to the suppression of 
cytoskeleton changes and cell migration. 
Cdc42 and Rac1, two main members of Rho GTPases, are crucial in the 
formation of filopodia and lamellipodia [Raftopoulou and Hall, 2004]. Moreover, 
both Cdc42 and Rac1 were reported to act as downstream effectors of PI3K in 
several growth factor stimulated pathways [Krasilnikov, 2000; Sturge et al., 2002]. 
To investigate whether the inhibitory effect of emodin on cell migration pertains to 
the activation of Cdc42 and Rac1, EGF-mediated Cdc42 and Rac1 activation was 
first examined. A Cdc42/Rac1 activation assay kit (from Upstate) was used to 
measure the activation level of Cdc42 or Rac1. This is a direct pull-down experiment 
performed by measuring the binding capability of GTP-bound Cdc42 or Rac1 to 
GST-PAK1 PBD fusion protein immobilized onto glutathione-agarose beads. As 
shown in Fig. 4.9, both Cdc42 and Rac1 were readily activated after 20ng/ml EGF 
stimulation. EGF induced a substantial but transient increase in active Cdc42. 
Maximum Cdc42 activation occurred between 10 to 30 minutes after EGF 
stimulation. In contrast, Rac1 is activated in a modest but sustained manner, reaching 
the maximum level after 30 minutes. Next, the effect of emodin and LY294002 on 
the activation of Cdc42 and Rac1 was measured. As shown in Fig. 4.10, emodin 
showed evident inhibitory effect on EGF-induced activation of both Cdc42 and Rac1 
in a concentration-dependent manner. LY294002 showed a similar suppressive 
effect. These results suggest that Cdc42 and Rac1, as downstream effector molecules 
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of PI3K, are likely to be involved in the inhibitory effect of emodin on EGF-induced 








Fig. 4.6 Representative images showing the effects of emodin and LY294002 on 
migration of CA-p110 transfected cells. Cells were transfected with empty vector or 
CA-p110, together with pDsRed. After 1 hr pretreatment of 40 μM emodin or 10 μM 































Fig. 4.7 Quantification of the effects of emodin on migration of CA-p110 
transfected cells. Cells were transfected with empty vector or CA-p110, together with 
pDsRed. After 1 hr pretreatment of 40 μM emodin or 10 μM LY294002, cells were 
subjected to migration assay in the absence (open columns) or presence (solid columns) 
of 20 ng/ml EGF. Data are presented as means ± SD of three independent experiments 
and expressed as percentage. (* p<0.05 compared to the control group without EGF; # 
























Fig. 4.8 Emodin inhibited EGF-induced filopodia and lamellipodia formation. 
Cells were stimulated with 20 ng/ml EGF for 30 min after 1 hr pretreatment with 40 
μM emodin or 10 μM LY294002. Cells were fixed and stained with FITC-conjugated 
phalloidin as indicated in Materials and Methods. Cells at higher magnification are 













Fig. 4.9 EGF induced activation of Cdc42 and Rac1. Cells were starved and 
stimulated with 20 ng/ml EGF for different time intervals. Cells were assayed for 
Cdc42/Rac1 activation using a PAK/GST-PBD pull down assay as described in 























Fig. 4.10 Effects of emodin and LY294002 on EGF-induced activation of Cdc42 
and Rac1. Cells were pretreated with 0-40 μM emodin or 10 μM LY294002 for 1 hr 
followed by 30 min stimulation with 20 ng/ml EGF. Cells were assayed for 
Cdc42/Rac1 activation using a PAK/GST-PBD pull down assay as described in 
































4.3.5 Emodin interfered with the formation of the Cdc42/Rac1 and PAK1 
complex  
To further confirm the involvement of Cdc42 and Rac1 in EGF-induced cell 
migration, the cells were transfected with DN-Cdc42 or DN-Rac1 vector and found 
that DN-Cdc42 and DN-Rac1 plasmids significantly reduced EGF-induced cell 
migration (Fig. 4.11; Fig. 4.14), suggesting that activation of Cdc42 and Rac1 is 
necessary for EGF stimulation of cell migration.  
To clarify whether the inhibitory effect of emodin on cell migration and 
activation of Cdc42/Rac1 is not just a consequence of inhibition of PI3K activity, 
cells were first transfected with CA-Cdc42 or CA-Rac1 plasmid, then treated with 
emodin or LY294002 for 1 hr, followed by measuring the level of Cdc42 or Rac1 
activation and a cell migration assay. As shown in the Fig. 4.12 and 4.15, emodin 
significantly suppressed cell migration in CA-Cdc42 and CA-Rac1-overexpressing 
cells, while LY294002 had no obvious effect. These data clearly suggest that the 
inhibitory effect of emodin on cell migration is not only a consequence of 
suppressing PI3K activation.  
One interesting finding here was that the Cdc42 and Rac1 activation level was 
deceased after emodin treatment in CA-Cdc42 and CA-Rac1 overexpressed cells, 
respectively (Fig. 4.12; Fig. 4.15). How could emodin “inhibit” the activity of 
constitutively active Cdc42 and Rac1 in the cell? In this experimental system, the 
Cdc42/Rac1 activation assay is basically a direct pull-down experiment performed 
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by measuring the binding of active form of Cdc42 or Rac1 to GST-PAK1 PBD. 
Therefore, it is possible that the “reduced activity” of Cdc42/Rac1 after emodin 
treatment in CA-Cdc42 or CA-Rac1-overexpressing cells might be due to the 
interference by emodin with the formation of active Cdc42/Rac1 and PAK1 
complex. To test this possibility, a co-immunoprecipitation assay was performed in 
CA-Cdc42 or CA-Rac1-overexpressing cells to examine the effect of emodin on the 
protein-protein interaction between Cdc42/Rac1 and PAK1. As shown in the Fig. 
4.13 and Fig. 4.16, emodin, but not LY294002, significantly suppressed the 
association of active Cdc42/Rac1 with PAK1. These data therefore confirm the 





























Fig. 4.11 Effects of overexpression of DN-Cdc42 on EGF-induced cell migration. 
MDA-MB-231 cells were transfected with empty vector or DN-Cdc42, together with 




























Fig. 4.12 Emodin inhibited migration of CA-Cdc42 transfected cells. 24 hr after 
transfection with empty vector or CA-Cdc42, together with pDsRed, cells were starved in 
FBS-free medium for another 24 hr. Then they were incubated with or without 40 μM 
emodin or 10 μM LY294002 for 1 hr. Cells were then assayed for Cdc42 activation (A) and 
motility (B), respectively, as described in Materials and methods. Migration data are 
presented as means ± SD of three independent experiments and expressed as percentage. (* 
























Fig. 4.13 Emodin interfered with the formation of Cdc42 and PAK1 complex. 
Cells were transfected with empty vector or CA-Cdc42, together with pDsRed, starved 
and treated with 40 μM emodin or 10 μM LY294002 for 1 hr. Cell lysates were 
immunoprecipitated (IP) with anti-PAK1 antibody followed by anti-Cdc42 
immunoblotting (IB). Data shown are representative of three experiments with similar 
results.  
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Fig. 4.14 Effect of overexpression of DN-Rac1 on EGF-induced cell migration. 
MDA-MB-231 cells were transfected with empty vector or DN-Rac1, together with 





























Fig. 4.15 Emodin inhibited migration of CA-Rac1 transfected cells. 24 hr after 
transfection with empty vector or CA-Rac1, together with pDsRed, cells were starved for 
another 24 hr. Then cells were treated with or without 40 μM emodin or 10 μM LY294002 
for 1 hr. Cells were assayed for Rac1 activation (A) and motility (B), respectively, as 
described in Materials and methods. Data are presented as means ± SD of three 




















Fig. 4.16 Effects of emodin on the formation of Rac1 and PAK1 complex. Cells 
were transfected with empty vector or CA-Rac1, together with pDsRed, starved and 
treated with 40 μM emodin or 10 μM LY294002 for 1 hr. Cell lysates were 
immunoprecipitated (IP) with anti-PAK1 antibody following by anti-Rac1 
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Emodin is an active component from the rhizome of Rheum palmatum and has 
been reported to possess anti-tumor effects in various cancer cells [Chang et al., 
1996]. However, little is known about its effect against tumor metastasis. In the 
previous chapter, emodin was observed to inhibit cancer cell invasion in both HSC5 
and MDA-MB-231 cells through suppression of AP-1 and NF-κB. In this chapter, 
the effect of emodin against cancer cell migration, and the molecular mechanisms 
involved, was further investigated. Nontoxic levels of emodin was found to 
efficiently suppress the migration of EGF-treated cancer cells, and this suppression is 
achieved through inhibiting PI3K activity and interfering with Cdc42/Rac1-PAK 
complex formation. 
PI3K is one of the most important regulatory proteins, involved in controlling 
several key functions of the cell, such as cell growth, aging and transformation. It 
consists of two subunits: p85 (85 kDa regulatory subunit) and p110 (110 kDa 
catalytic subunit). The activation of PI3K occurs through interaction with receptor 
(growth factor receptors) or non-receptor tyrosine kinases [Krasilnikov, 2000]. 
Among the main downstream effectors of PI3K, Akt is mainly involved in the 
control of apoptosis; and Ras/Raf/Erk pathway regulates cell growth and division. A 
role for PI3K in the regulation of cell migration has been well documented [Derman 
et al., 1997; Sotsios and Ward, 2000]. Activation of the PI3K p110 subunit in breast 
cancer cells has been reported to be necessary for EGF-induced actin nucleation [Hill 
et al., 2000], an important cytoskeleton change for cell migration. In this study, the 
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critical role of PI3K was confirmed in EGF-induced cell migration in MDA-MB-231 
cells, based on the following observations. First, EGF enhanced Akt phosphorylation 
which is blocked by a specific PI3K inhibitor (LY294002) (Fig. 4.4); second, 
overexpression of DN-p110, as well as LY294002, abolished EGF-induced cell 
migration (Fig. 4.2 and 4.5); and third, LY294002 and DN-p110 inhibited 
EGF-induced Cdc42 and Rac1 activation and the formation of lamellipodia and 
filopodia (Fig. 4.10, Fig. 4.3 and data not shown). These data indicate that PI3K 
activation plays a critical role in mediating EGF-induced cell migration in 
MDA-MB-231 cells.  
In this part of study, emodin was found to suppress EGF-induced migration in a 
number of human cancer cell lines (Fig. 4.1). A previous report demonstrated that 
emodin is an inhibitor of PI3K in a cell-free kinase assay system [Frew et al., 1994]. 
It was thus hypothesized that inhibition of PI3K pathway was the underlying 
mechanism responsible for the effect of emodin against cell migration. This 
hypothesis is supported by the observation that emodin suppressed the 
phosphorylation level of Akt, a well defined downstream effector of PI3K (Fig. 4.4). 
In addition, emodin inhibited the migration of cells transfected with CA-p110 vector 
(Fig. 4.6 and 4.7). The above finding is basically consistent with previous reports on 
inhibition of PI3K pathway and suppression of cell migration by some other 
chemopreventive agents such as red wine polyphenols [Iijima et al., 2002], sulindac 
sulfide and caffeic acid phenethyl ester [Shigeoka et al., 2003]. 
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The organized polymerization of actin filaments is believed to be an important 
mechanism required for cell migration [Pawlak and Helfman, 2001]. Among several 
cell structures related to cell migration, lamellipodia are broad flat membrane 
extensions and generally formed through the polymerization of filamentous (F)-actin, 
while filopodia are often found at the edges of the lamellipodia and are also the result 
of actin polymerization [Raftopoulou and Hall, 2004]. The Rho GTPases are reported 
to be key regulators of actin dynamics that lead to organized actin-based structures 
associated with cell migration. Activated Cdc42 and Rac1 stimulate filopodia and 
lamellipodia formation respectively [Price and Collard, 2001]. In the present study, 
EGF induced significant actin cytoskeleton changes and emodin markedly inhibited 
the EGF-induced formation of filopodia and lamellipodia (Fig. 4.8), which is 
consistent with the finding that emodin inhibited EGF-induced activation of Cdc42 
and Rac1 (Fig. 4.10).  
Being downstream of PI3K, Cdc42 and Rac1 are the two important GTPases that 
have been implicated in many cellular processes, such as cytoskeleton 
rearrangement, cell adhesion and transcriptional activation, and are believed to be 
involved in cancer cell migration, invasion and metastasis [Schmitz et al., 2000; 
Price and Collard, 2001]. One important Cdc42/Rac1 effector is PAKs, which also 
play a critical role in cytoskeleton reorganization and cell migration [Vadlamudi and 
Kumar, 2003]. By direct interaction of their PBD with GTP-bound Cdc42 or Rac1, 
PAKs undergo a conformational change that allows autophosphorylation and 
activation [Abo et al., 1998]. Downstream targets for PAKs include MLCK and 
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LIMK that are known to be involved in migration. MLCK phosphorylates myosin 
light chain, which is important in regulating actin cytoskeleton dynamics [Sanders et 
al., 1999]. In addition, PAK phosphorylates and activates LIMK, which in turn 
phosphorylates and inactivates the actin-severing protein cofillin, thus promoting 
filament assembly [Edwards et al., 1999]. In this part of study, emodin, but not 
LY294002, was found to inhibit the migration of CA-Cdc42 or 
CA-Rac1-overexpressing cells (Fig. 4.12; Fig. 4.15). Besides, emodin significantly 
interfered with the formation of Cdc42/Rac1 and PAK1 complex (Fig. 4.13; Fig. 
4.16), while LY294002 had no such effect. This interference might lead to PAK1 
inactivation and, in turn, affect the downstream cytoskeletal targets of PAK. These 
results suggest that, besides its inhibitory effect on PI3K activity, emodin might also 
inhibit cell migration through another mechanism - disrupting the formation of an 
active Cdc42/Rac1 and PAK complex.  
Active migration of tumor cells is a prerequisite for tumor metastasis and cancer 
development and progression. Inhibition of tumor cell motility has been considered 
as an effective approach for the suppression of cancer invasion and metastasis. In this 
part of study, convincing evidence was provided that emodin was able to inhibit the 
EGF-induced cell migration through two independent mechanisms: (1) by 
suppressing the PI3K activity and (2) by disrupting the formation of Cdc42/Rac1 and 
PAK complex. Such findings suggest that this anthraquinone interferes with tumor 
progression at several pivotal points and it could be used as a chemotherapeutic agent 













EMODIN INHIBITS TUMOR CELL ADHESION THROUGH DISRUPTION 





Cancer metastasis consists of a complex cascade of biological events, including 
adhesion, migration and invasion, which finally allow tumor cells to escape from 
primary site and invade and proliferate at ectopic environments [Woodhouse et al., 
1997; Bogenrieder and Herlyn, 2003]. Cell adhesion and spreading is a crucial step in 
the metastatic cascade of cancer cells. Interruption of this step is considered to be a 
logical strategy for prevention and treatment of tumor metastasis.  
It has been well established that cell adhesion and spreading is mediated by a 
variety of transmembrane proteins, including integrins, cadherins, selectins, and 
intercellular adhesion molecules [Woodhouse et al., 1997; Bogenrieder and Herlyn, 
2003]. Among these adhesion molecules, the integrins and their downstream signaling 
pathways have been extensively studied. Integrins are α/β-heterodimeric membrane 
proteins that facilitate the anchorage of cells to the components of ECM [Hynes, 2002]. 
The attachment of cells to certain ECM proteins such as fibronectin, collagen and 
laminin, leads to the clustering of integrins, with subsequent formation of focal 
adhesion [Danen, 2005]. Several cytoplasmic proteins are recruited into focal 
adhesions, such as FAK, c-Src, paxillin, as well as vinculin [Wozniak et al., 2004]. 
Specifically, FAK is a key regulator of cell adhesion and migration. Interaction of β 
subunit of integrins and FAK causes kinase autophosphorylation at Y397 of FAK 
where c-Src targets. c-Src further fully phosphorylates and activates FAK, which 
recruits additional structural and signaling molecules to contribute to the assembly of 
focal adhesion complex (FAC) [Wozniak et al., 2004; Mitra et al., 2005].  
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Lipid rafts are distinct plasma membrane microdomains, comprised of cholesterol 
tightly packed with sphingolipids, in particular sphingomyelins, and may serve as 
signaling platforms to recruit essential proteins for intracellular signal transduction 
and coordinate transmembrane signaling and cell adhesion [Simons and Ikonen, 1997; 
Manes et al., 1999]. Importantly, integrins have been recently found to be lipid raft 
associated [Pande, 2000]. The function of integrins, such as integrin α4β1, was 
reported to be positively regulated by the lipid rafts in T lymphocytes [Leitinger and 
Hogg, 2002]. The attachment of cells to ECM proteins is deficient when cells are 
totally devoid of sphingolipids [Hidari et al., 1996].  
In Chapter 3 and Chapter 4, emodin exhibits strong inhibitory effect on cancer cell 
invasion and migration. Since cell adhesion is another important event in the 
metastatic cascade of cancer cells, in this Chapter, the effect of emodin on cancer cell 
adhesion, as well as the possible mechanisms involved, was further investigated.  
5.2 Materials and Methods 
5.2.1 Cell lines 
MDA-MB-231 (a human breast cancer cell line), HeLa (a human cervix epitheloid 
carcinoma cell line) and HepG2 (a human hepatocarcinoma cell line) were purchased 
from ATCC (Manassas, VA). HSC5, derived from human skin squamous carcinoma, 
was kindly provided by Dr. S. Kondo (Yamagata University, Yamagata, Japan). 
MDA-MB-231, HeLa and HSC5 cells were cultured in DMEM supplemented with 
10% FBS. HepG2 cells were grown and passaged in MEM containing 10% FBS. 
5.2.2 Chemicals and reagents 
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Emodin, laminin, collagen I, fibronectin, soluble cholesterol, 
methyl-β-cyclodextrin (MBCD) and anti-vinculin antibody were purchased from 
Sigma (St. Louis, MO). Antibodies against paxillin, FAK, phospho-FAK (Y397) and 
c-Src were purchased from Santa Cruz Technology (Santa Cruz, CA). Sepharose 4B 
was from Amersham Bioscience (Uppsala, Sweden). cRGDfV and GRGDTP were 
from Calbiochem (San Diego, CA). Purified human integrin α1β1 and α5β1, and 
antibodies against integrin α2β1, α5β1, α1β1, and β1 were from Chemicon 
(Temecula, CA). Alexa Flour 488 conjugated Cholera toxin subunit B (CTxB) and 
antibody against transferrin receptor (TfR) were from Life Technologies (Invitrogen, 
CA). Lipid internal standards (cholesterol, ceramide, ceramide glucoside and 
sphingomyelin) were purchased from Avanti Polar Lipids (Alabaster, AL), and 
[26,26,26,27,27,27-d6]cholesterol was from CDN Isotopes (Quebec, Canada). All the 
solvents were HPLC grade and purchased from Merck (Whitehouse Station, NJ). 
5.2.3 Cell adhesion and spreading assay 
Adhesion and spreading assay were performed as described previously with 
modifications [Twal et al., 2001].  
(1)  96-well plates were coated with fibronectin (5 μg/ml), collagen I (5μg/ml), 
laminin (10 μg/ml), or heat-denatured BSA 1% at 4°C overnight, washed with PBS 
and blocked in 1% BSA for 1 hr.  
(2) Serum-starved cells were harvested using cell dissociation solution (Sigma), 
and resuspended in FBS-free medium/0.1% BSA.  
(3) Cells were then treated according to the context for 1 hr.  
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(4) Cells (2×105/ml) were seeded onto the plates with different coatings as 
described above, and incubated for 20 min at 37°C.  
(5) Non-adherent cells were removed by gentle washing with PBS.  
(6) Adherent cells were fixed and stained with 0.1% crystal violet in 20% 
methanol. Incorporated dye was dissolved in 10% acetic acid and the absorbance was 
measured at 560 nm. The results were presented as percentage attachment, where 
100% attachment corresponds to the attachment of untreated cells exposed to 
fibronectin, collagen or laminin respectively. 
For the cell spreading assay, cells were treated with emodin as described in the cell 
adhesion assay, and seeded onto the plates with different coatings. After 1 hr 
incubation cells were fixed without washing. Spread cells were defined as those cells 
that had lost their phase bright appearance and had readily distinguishable nucleus and 
cytoplasm, and quantified by counting six randomly selected fields in each well under 
a phase-contrast microscope. 
5.2.4 Immunocytochemical staining and visualization of lipid rafts 
(1) Cells were pretreated for 1 hr according to the context and seeded onto 
coverslips coated with fibronectin.  
(2) After designated time intervals, cells were fixed with 2% paraformaldehyde 
in PBS, and permeabilised with 0.5% Triton X-100.  
(3) After blocking with 2% BSA for 30 min, the primary antibodies were layered 
onto cells and incubated in a moist chamber overnight at 4°C.  
(4) Cells were then washed and incubated with respective fluorescently tagged 
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secondary antibodies for 1 hr at 4°C.  
(5) Coverslips were mounted onto slides using SlowFade® light anti-fade kit 
(Molecular Probes, Eugene, Oregon).  
(6) Cells were then visualized using Olympus Fluoview FV500 confocal 
microscope (Melville, New York) and photographed.  
The labeling of membrane lipid rafts with CTxB was conducted as reported 
previously with slight modifications [Shen et al., 2004]. Cells were fixed in 2% 
paraformaldehyde for 20 min on ice, followed by incubation with 5 μg/ml 
FITC-conjugated CTxB for 20 min. The co-staining of integrin β1 was then performed 
as described above. 
5.2.5 Separation of proteins between detergent-soluble and 
detergent-insoluble fractions 
Separation of proteins between detergent-soluble and detergent-insoluble 
fractions was conducted as described previously with modifications [Tai et al., 2003]. 
(1) After designated treatments, cells were plated onto fibronectin-coated culture 
dishes. 
(2) Cells were incubated for 0, 5, 10, 20, 40 min before lysed in ice-cold lysis 
buffer (150mM NaCl, 0.5% Triton X-100, 20mM Tris, pH 7.5) with proteinase 
inhibitor cocktail (Roche).  
(3) The lysates were centrifuged at 14,000 × g for 30 min at 4°C, and the 
supernatants were collected as the detergent-soluble fraction.  
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(4) The detergent-insoluble pellets were resuspended and briefly sonicated in the 
same lysis buffer supplemented with 0.5% SDS and 2 mM DTT.  
(5) The proteins were then subjected to SDS-PAGE and visualized by 
immunoblotting. 
5.2.6 Co-Immunoprecipitation and Western Blot 
The experiment procedures for Co-Immunoprecipitation and Western blot were 
described in detail in Chapter 4 and Chapter 3, respectively. In brief, cell lysates were 
prepared with co-immunoprecipitation lysis buffer (50mM HEPES, pH 7.6, 250 mM 
NaCl, 0.1% NP-40, 5mM EDTA, 0.5mM PMSF and the proteinase inhibitor cocktail). 
500 µg of cell lysates were first incubated with 5µg of designated antibodies for 1 hr at 
4°C, followed by incubation with protein A-Sepharose beads for another 1 hr at 4°C. 
The beads were washed three times with ice-cold co-immunoprecipitation lysis buffer, 
resolved by SDS-PAGE, and immunoblotted with antibodies against various proteins 
of interest. 
5.2.7 Measurement of cell surface integrins with flow cytometry 
(1) After designated treatments, cells were collected and fixed with 2% 
paraformaldehyde in PBS.  
(2) After washing with PBS, cells were then incubated with antibodies against 
integrin α1β1, α2β1, or α5β1 for 1 hr. As a negative control, cells were stained with 
isotype-matched immunoglobulin G (IgG).  
(3) Cells were then incubated with FITC-conjugated secondary antibody for 
another 1 hr. 
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(4) Cells were resuspended in 500 μl of PBS for cytometric analysis.  
5.2.8 Solid-phase binding assays with purified integrins 
Effect of emodin on integrin binding was quantified by measuring the interactions 
between integrins and their immobilized ligands, based on an established ELISA-type 
protocol with minor modifications [Pfaff et al., 1994]. Briefly:  
(1) 96-well plates were coated with fibronectin (5 μg/ml), collagen I (5 μg/ml), 
laminin (10 μg/ml) or 1% BSA, all dissolved in coating buffer (20mM Tris-HCl, pH 
7.4, 0.15M NaCl, 1mM CaCl2 and 1mM MgCl2), at 4°C overnight.  
(2) The plates were then blocked with 1% BSA in coating buffer for 1 hr at room 
temperature.  
(3) Integrin α5β1 or α1β1 at 0.2 μg was added and incubated with or without 
emodin for 2 hr at 37°C.  
(4) After washing away the unbound integrins, primary antibody against integrin 
β1 was added to the plates and incubated for 2 hr followed by incubation with second 
antibody (anti-mouse IgG-HRP) for 1 hr.  
(5) Horseradish peroxidase activity was determined with 
3,3’,5,5’-tetramethylbenzidine/H2O2 as a substrate and optical density was measured 
at 450 nm. The amount of nonspecific binding was determined using wells coated with 
BSA alone. 
5.2.9 Lipid extraction 
Lipid extraction was carried out using a modified Bligh and Dyer method [Bligh 
and Dyer, 1959].  
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(1) Separation of detergent-soluble and -insoluble fractions was conducted as 
described above.  
(2) 50 μl cold PBS and 0.6 ml of chloroform: methanol (1:2) were added directly 
into detergent-insoluble pellets.  
(3) After vigorous vortex and brief incubation on ice, 0.3ml of chloroform and 
0.2ml 1M KCl were added.  
(4) The organic layer (lower phase) was then separated and dried.  
(5) Dried lipid film was resuspended in chloroform: methanol (1:1) for mass 
spectrometry (MS) analysis. 
5.2.10 Electrospray ionisation (ESI)/MS and APCI analysis of lipids 
MS analysis of cholesterol was carried out at atmosphere pressure chemical 
ionization (APCI) positive mode with an Applied Biosystems 4000 Q-Trap mass 
spectrometer (Applied Biosystems, Foster City, CA).  
(1) Multiple reaction mechanism (MRM) transitions of 369/161 and 375/161 
were established for quantification of cholesterol (Shui G, et al, paper in preparation).  
(2) 20 μl of sample was introduced into the MS using an Agilent high throughput 
liquid chromatography (HTLC) system with chloroform/methanol (1:1) as a mobile 
phase at a flow rate of 200 μl/min.  
(3) The APCI conditions were: vaporizer temperature, 500°C; corona discharge 
current, 3 μA.  
(4) For method validation, different amounts of cholesterol standards were added 
into cell extracts to test the linearity. The intensities of individual ions were compared 
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with their corresponding internal standard species.  
(5) The relative content of each individual ion in untreated insoluble fraction was 
normalized to 1, and the results were expressed as relative content of treated groups 
compared to that of control group.  
Based on ESI/MS, ESI/MS/MS and ESI/MS/MS/MS (MS3) data obtained from a 
Q-TOF mass spectrometer (Waters, Milford, Massachusetts) and an AB 400 Q-Trap 
mass spectrometer, major sphingolipids in insoluble fractions were analyzed using 
MRM at ESI negative mode on the Q-Trap mass spectrometer. MRM transitions for 
sphingolipids were set up based on fragmentation patterns of ceramide heads of 
sphingolipids [Han and Cheng, 2005; Merrill et al., 2005]. Typically, 20 μl of sample 
was introduced into the MS using an Agilent HTLC system with chloroform/methanol 
(1:1) as a mobile phase at a flow rate of 200 μl/min. The ion spray voltage and 
temperature were set at 4500 V and 250°C, respectively. Nitrogen was used as curtain 
gas (value of 20) and collision gas was set to high. 
5.2.11 Statistics  
The results obtained from each experiment are expressed as mean ± SD of 
triplicates. The significance level was set at p<0.05 for each analysis using Student’s 
t-test. 
5.3 Results 
5.3.1 Effect of emodin on cancer cell adhesion and spreading 
In Chapter 3 and Chapter 4, emodin has been found to possess strong inhibitory 
effect on the invasion and migration of cancer cells. As cell adhesion is one of the 
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essential steps involved in cancer metastasis, in this chapter, the effect of emodin on 
cancer cell adhesion was further investigated. First, the effect of emodin on cell 
adhesion to fibronectin, a major ECM component [Danen, 2005], was examined. The 
experiment was conducted using four different cancer cell lines, including 
MDA-MB-231, HSC5, HepG2, and HeLa cells. As shown in Fig. 5.1, presence of 
fibronectin on the culture surface significantly enhanced cell adhesion compared with 
BSA. Emodin suppressed cancer cell adhesion to fibronectin in a dose-dependent 
manner. For instance, at 40 μM, emodin inhibited 70% of adhesion compared to 
fibronectin control group. Also, the effect of emodin on cell adhesion to collagen I and 
laminin, two other major components of ECM [Danen, 2005], was examined. Emodin 
showed similar inhibitory effect in a dose-dependent fashion in MDA-MB-231 cells 
(Fig. 5.2). Furthermore, the effect of emodin on cell spreading, another common 
approach to assess cell adhesion, was also tested. Results in Fig. 5.3 show that emodin 
significantly suppressed cell spreading on fibronectin, collagen or laminin. With 
emodin treatment, most of the cells showed defects in polarized extension and 



























Fig. 5.1 Effects of emodin on adhesion of MDA-MB-231, HSC5, HepG2, and 
HeLa cells to fibronectin (FN). Serum-starved cells were harvested and pretreated 
with emodin (0-40 μM × 1 hr) and then seeded onto fibronectin (FN) (5μg/ml) or 1% 
BSA-coated 96-well plates. Adhesion assay was conducted as described in Materials 
and Methods. Data are presented as means ± SD of three independent experiments and 





























Fig. 5.2 Effects of emodin on adhesion of MDA-MB-231 cells to fibronectin 
(FN), collagen (CL), or laminin (LM). Serum-starved MDA-MB-231 cells were 
harvested and pretreated with emodin (0-40 μM × 1 hr) and then seeded onto 
fibronectin (FN) (5μg/ml), collagen I (CL) (5 μg/ml), laminin (LM) (10 μg/ml) or 
1% BSA-coated 96-well plates. Adhesion assay was conducted as described in 
Materials and Methods. Data are presented as means ± SD of three independent 

































Fig. 5.3 Effects of emodin on spreading of MDA-MB-231 cells to FN, CL or LM. 
Serum-starved MDA-MB-231 cells were harvested and pretreated with emodin (0-40 
μM × 1 hr) and then seeded onto fibronectin (FN) (5μg/ml), collagen I (CL) (5 
μg/ml), laminin (LM) (10 μg/ml) or 1% BSA-coated 96-well plates. Spreading assay 
was conducted as described in Materials and Methods. (Upper panel: images of cell 
spreading on FN, CL or LM-coated surface; Lower panel: quantitative data based on at 








5.3.2 Inhibitory effect of emodin on focal adhesion formation 
Focal adhesion formation is an essential step in cell adhesion [Carragher and 
Frame, 2004]. In an effort to understand the mechanisms involved in the inhibitory 
effect of emodin on cell adhesion, the effect of emodin on the distribution of FAK, 
paxillin and vinculin, three major components of focal adhesions, was examined using 
immunofluorescence staining. As shown in Fig. 5.4, focal adhesions were formed both 
at the central and peripheral parts of cells after 60 min attachment. In contrast, emodin 
treatment led to the reorganization of FAK, paxillin and vinculin into granule-like or 
diffused pattern of staining. Meanwhile, consistent with the result in Fig. 5.3, cells 
treated with emodin remained rounded with significantly reduced cell flattening and 
spreading.  
5.3.3 Effect of emodin on ligand binding and expression level of integrins 
The data presented above have clearly demonstrated the inhibitory effect of 
emodin on focal adhesion formation. It is generally accepted that integrins mediate the 
focal adhesion formation and subsequent attachment of cells to ECM [Wozniak et al., 
2004; Mitra et al., 2005]. Therefore, such inhibitory effect could be achieved via the 
following mechanisms: (i) direct interference on the integrin-ligand binding, (ii) 
down-regulation of integrin expression level on cell surface, and (iii) disruption on the 
integrin-mediated signaling pathway. Here, the effect of emodin on the functionality of 
integrin α5β1 (fibronectin receptor) and α1β1 (collagen I, IV and laminin receptor) 
was investigated by testing its effect on the interactions between integrins and 
immobilized ligands. As shown in Fig. 5.5, GRGDTP, a cell adhesion inhibitor, 
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suppressed integrin α5β1 binding to fibronectin in a dose-dependent manner, while 
emodin did not show obvious effect. Similar minimal effect of emodin was observed 
on suppressing the binding of integrin α1β1 and collagen or laminin, respectively. 
cRGDfV, serving as a positive control, decreased the binding dose-dependently (data 
not shown). These data suggest that emodin has no significant effect on the binding of 
integrins and their ligands.  
Meanwhile, to verify the possible effect of emodin on integrin expression levels, 
the surface expression of integrins was measured using flow cytometry. It was found 
that emodin had no significant effect on the surface expression of integrin α2β1, α5β1 
and α1β1 (Fig. 5.6). The overall expression level of integrin receptors was also 
measured after fixing and permeabilizing the cells with 70% ethanol and found no 
obvious change on overall expression of integrins after emodin treatment (data not 
shown). These data suggest that emodin has no remarkable effect on both the surface 














Fig. 5.4 Emodin impaired focal adhesion formation. MDA-MB-231 human breast 
cancer cells were pretreated with or without 40 μM emodin for 1 hr and seeded onto 
FN-coated Coverslips for 1 hr. Then cells were fixed and immunostained with 
anti-FAK, anti-paxillin or anti-vinculin antibodies as described in Materials and 
Methods. Images were examined and photographed by confocal microscopy. Scale 

































Fig. 5.5 Emodin showed no effect on integrin ligand binding. The integrin ligand 
binding was determined using an ELISA method, as described in Material and 
Methods. Results are expressed as percentage comparing to the control group without 
















Fig. 5.6 Emodin showed no effect on integrin expression level on cell surface. 
MDA-MB-231 cells were pretreated with or without 40 μM emodin for 1 hr and 
seeded onto FN or BSA-coated Petri dishes for additional 1 hr. Cells were then 
collected, fixed and incubated with anti-α1β1, anti-α2β1 or anti-α5β1 antibody. 
Negative control was stained with isotype-matched IgG. After incubating with 
FITC-conjugated secondary antibody, cells were resuspended in PBS and subjected to 











5.3.4 Effects of emodin on the recruitment of FAK to integrins and formation 
of FAC 
Since emodin has no significant effect on either integrin-ligand binding or integrin 
expression, the next step was to examine its possible effect on integrin-mediated 
signaling pathway. It is well reported that the recruitment of FAK to activated integrins 
is an early consequence of integrin ligand interaction, followed by rapid 
autophosphorylation of FAK-Tyr397 [Kumar, 1998; Wozniak et al., 2004; Mitra et al., 
2005]. Thus, the association of FAK with integrin β1, a common integrin subunit 
involved in cell adhesion to fibronectin, collagen and laminin, was tested. 
Immunoprecipitation (IP) analysis revealed that attachment to fibronectin 
significantly induced association of FAK with integrin β1 (Fig. 5.7). This association 
was maximal around 20 minutes after seeding and decreased afterwards. Treatment 
with emodin resulted in evident inhibition on the association of FAK with integrin β1 
in a time-dependent manner, suggesting that the recruitment of FAK to integrin β1 was 
disrupted with emodin treatment. Similarly, when further examining the effect of 
emodin on the phosphorylation of FAK-Tyr397, an event following the recruitment of 
FAK to activated integrins [Kumar, 1998; Wozniak et al., 2004; Mitra et al., 2005], it 
was found that the presence of fibronectin markedly enhanced FAK-Tyr397 
phosphorylation. Emodin treatment caused a dramatic decrease in the phosphorylation 
level of FAK-Tyr397 in a time-dependent fashion (Fig. 5.8).  
 139 
Furthermore, the effect of emodin on direct protein-protein interaction within FAC 
was examined. As shown in Fig.5.9A, there was an increased association of FAK with 
paxillin and vinculin after cell exposure to fibronectin. Maximum association occurred 
around 20 minutes after seeding. Treatment with emodin resulted in obvious inhibition 
on the association of FAK with the other two focal adhesion molecules in a 
time-dependent manner, suggesting that FAC formation was disrupted with emodin 
treatment. To confirm the above finding, a reverse co-IP using anti-paxillin antibody 
was performed. As shown in Fig. 5.9B, emodin markedly suppressed the association 
of paxillin with FAK and vinculin in a dose-dependent manner. Taken together with 
the data in Fig. 5.7 and 5.8, these results suggest that emodin might disrupt the 
integrin-mediated signaling cascade through inhibiting the recruitment of FAK to 










Fig. 5.7 Emodin suppressed the recruitment of FAK to integrin β1. MDA-MB-231 
cells were pretreated with or without emodin for 1 hr and seeded onto Petri dishes 
coated with FN or BSA. Cell lysates were immunoprecipitated with antibody against 
integrin β1 and immunoblotted with antibody against FAK after cells were seeded for 






















Fig. 5.8 Emodin inhibited the phosphorylation of FAK Y397. MDA-MB-231 cells 
were pretreated with or without emodin for 1 hr. After cells were seeded onto Petri 
dishes coated with FN or BSA for designated period of times, whole cell lysates were 






















Fig. 5.9 Emodin suppressed the formation of focal adhesion complex. 
MDA-MB-231 cells were pretreated with or without emodin for 1 hr. After cells were 
seeded onto Petri dishes coated with FN or BSA for designated period of times, cell 
lysates were immunoprecitated with an anti-FAK antibody and immunoblotted with 
antibody against paxillin and vinculin (A), or immunoprecitated with an anti-paxillin 
antibody and immunoblotted with antibody against FAK and vinculin (B). 
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5.3.5 Emodin inhibited the lipid raft clustering and subsequent association of 
integrin β1 and FAC proteins with lipid rafts. 
It is reported that the recruitment of FAK to integrins is the consequence of integrin 
clustering induced by interaction with specific ligands [Kumar, 1998; Wozniak et al., 
2004]. Thus, to further explore the underlying mechanism involved,  the next step 
was to investigate the possible effect of emodin on integrin clustering. Recently, lipid 
raft, a microdomain rich in sphingolipids and cholesterol, has been increasingly 
recognized to play a critical role in modulating the integrin clustering and functions 
through raft coalescence mechanism [Pande, 2000; Helms and Zurzolo, 2004]. 
Therefore, in this study, confocal microscopy was used to validate whether there is 
lipid raft and integrin clustering, as well as the colocalization of lipid rafts and integrin 
β1 upon cell-matrix interaction. Owing to its highly specific binding to 
raft-ganglioside GM1, Alaxa Flour 488-conjugated CTxB was used to visualize 
membrane rafts [Shen et al., 2004]. Meanwhile, cells were co-stained with 
anti-integrin β1 antibody (in red fluorescence). The results in Fig. 5.10 show that cell 
attachment to fibronectin quickly led to significant coalescence of lipid rafts into 
distinct larger patches. At the same time, clustering of integrin β1 was also observed. 
The colocalization of integrin β1 with lipid raft patches happened within 10 min after 
seeding and started to decrease after 20 min. These results demonstrate the rapid 
association of integrin β1 with membrane rafts after cell exposure to fibronectin. 
Based on these observations, it was subsequently tested whether emodin has any 
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effect on the raft and integrin β1 clustering, and colocalization of integrin β1 and lipid 
rafts 10 min after seeding. As shown in Fig. 5.11, after emodin treatment, no obvious 
integrin β1 clustering was observed. The colocalization of integrin β1 with raft patches 
was also inhibited by emodin. Another interesting finding is that emodin inhibited the 
lipid raft clustering, similar to that of Methyl-β-cyclodextrin (MBCD), a known 
inhibitor of lipid raft formation [Kilsdonk et al., 1995]. These results are consistent 
with the data in Fig. 5.7-9, and suggest that emodin might affect raft and integrin 
clustering, followed by inhibiting FAC formation and cell adhesion.  
To further verify this hypothesis, the functional association of lipid raft, integrins, 
as well as FAC molecules, was examined using nonionic detergent fractionation 
methods. Membrane rafts are microdomains of the plasma membrane enriched with 
cholesterol and sphingolipids. They are insoluble after treatment with nonionic 
detergents such as Triton X-100 at 4°C [Manes et al., 1999]. First, the distribution of 
integrin β1 between the detergent-soluble and detergent-insoluble fractions of 
MDA-MB-231 cells was measured. Integrin β1 was primarily present in the soluble 
fraction before exposure to fibronectin (data not shown), but started to transfer to the 
insoluble fraction shortly 5 min after seeding. This translocation lasted for about 20 
min and ended by returning of integrin β1 from membrane rafts (insoluble) to non-raft 
(soluble) fraction (Fig. 5.12A), demonstrating the temporal sequence and dynamic 
association of integrin β1 with membrane rafts. Meanwhile, the distribution of FAC 
proteins between the detergent-soluble and -insoluble fractions was also tested. Upon 
cell exposure to fibronectin, FAK, paxillin and vinculin were found translocated from 
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the soluble fraction to the insoluble fraction, similar to that of integrin β1. However, 
their translocation last much longer. These proteins still remained in the insoluble 
fraction 40 mins after seeding, while integrin β1 molecules have mostly returned to the 
soluble fraction. These results suggest that lipid rafts are essential in integrin-mediated 
signaling, and exposure to fibronectin induces the translocation of integrin β1, 
followed by FAC proteins, from non-rafts to rafts on the membrane. Besides, it is 
reported that c-Src is associated exclusively with membrane rafts, and TfR could serve 
as a non-raft marker [Lacalle et al., 2002]. Here it was found that substantial amount of 
c-Src mainly existed in the insoluble fraction (Fig. 5.12A), but not in the soluble 
fraction (data not shown). In contrast, TfR was mainly in the soluble fraction (data not 
shown) and hardly detectable in the insoluble fraction (Fig. 5.12A). This further 
confirms the quality of the sample preparation in this study.   
Based on these observations, the effect of emodin on the distribution of integrin β1 
and FAC molecules was tested 10 min after seeding. Emodin, as well as MBCD, 
markedly suppressed the translocation of integrin β1, FAK, paxillin and vinculin from 
the soluble fraction to insoluble fraction after seeding (Fig. 5.12B). Taken together 
with the data in Fig. 5.11, these results confirm that the inhibition of emodin on cell 
adhesion is through its suppression on lipid raft clustering, and subsequent 















Fig. 5.10 Cell exposure to FN induced lipid rafts and integrin clustering, and the 
colocalization of integrin β1 with lipid rafts. MDA-MB-231 cells were fixed at 0, 5, 10, 
20 min after seeding onto FN-coated surface. Cells were co-stained with Alexa Flour 
488-conjugated CTxB (green) and anti-integrin β1 (red) as described in Materials and 
Methods. Cells were analyzed by confocal microscopy. A representative cell (×600) is 
shown for each treatment. 
 


















Fig. 5.11 Emodin inhibited the lipid rafts and integrin clustering, and the 
colocalization of integrin β1 with lipid rafts. Cells were pretreated with 40 μM emodin 
or 2 mM MBCD for 1 hr and seeded onto FN-coated coverslips for 10 min, followed 
by immunostaining with Alexa Flour 488-conjugated CTxB (green) and integrin β1 
antibody (red). Cells were analyzed by confocal microscopy. A representative cell 
(×600) is shown for each treatment. 
 
















Fig. 5.12 Emodin suppressed the association of integrin β1 and FAC molecules 
with membrane lipid rafts. A, MDA-MB-231 cells were seeded onto FN-coated Petri 
dishes for up to 40 min. Detergent-insoluble (proteins rich in membrane raft) fractions 
of cell lysates were separated as described in Materials and Methods and subjected to 
10% SDS-PAGE, and immunoblotted with anti-integrin β1, FAK, paxillin, vinculin, 
c-Src and transferrin receptor (TfR) antibodies, respectively. Data are representative of 
three independent experiments. B, cells were first treated with emodin (40 μM) or 
MBCD (2 mM) for 1 hr, and then seeded onto FN or BSA-coated Petri dishes for 10 
min. Detergent-insoluble fractions of cell lysates were subjected to SDS-PAGE and 
























5.3.6 Effect of emodin on the change of cholesterol level and lipid profile 
To further explore the disruptive effect of emodin on lipid rafts, it was explored 
whether emodin would alter the lipid profiling of membrane rafts. Cholesterol is 
known to be one of the major components of lipid rafts [Helms and Zurzolo, 2004]. In 
this study, the APCI/MS analysis shows that the cholesterol content in the insoluble 
fraction decreased by ∼16% in the emodin-treated cells compared with the control 
group, similar to the effect of MBCD (Fig. 5.13). Whole cell cholesterol content 
remained the same with or without emodin treatment (data not shown). These results 
suggest that emodin treatment leads to evident decrease of cholesterol in the raft 
fraction. 
Since sphingolipids are another critical component of lipid rafts [Helms and 
Zurzolo, 2004], the effect of emodin on lipid profile was also examined. Fig. 5.14 
shows the ESI/MS profiles of lipid extracts from detergent insoluble fractions. Emodin 
induced remarkable decrease of various major sphingolipids in the insoluble fractions, 
including sphingomyelin 18/24:0, sphingomyelin 18/16:1, ceramide glycoside 18/24:0, 
ceramide 18/16:0, ceramide 18/24:0 and ceramide 18/24:1. Similar decrease was 
observed after MBCD treatment (data not shown). 
5.3.7 Cholesterol replenishment restored the translocation of integrin β1 and 
FAC molecules to lipid raft, and cell adhesion inhibited by emodin. 
To further confirm the involvement of cholesterol in the inhibitory effect of 
emodin on cell adhesion, the cholesterol replenishment experiment was performed. As 
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shown in Fig. 5.13, cholesterol replenishment (30 μg/ml) completely restored the 
cholesterol level of raft fraction in cells treated with emodin or MBCD. It was also 
observed that cholesterol replenishment effectively restored the sphingolipids 
decrease induced by emodin (Fig. 5.14) or MBCD (data not shown). These data 
suggest that emodin induced cholesterol-dependent decrease of sphingolipids in the 
lipid raft structure. 
Moreover, cholesterol replenishment totally abolished the inhibitory effect of 
emodin, as well as MBCD, on translocation of integrin β1 and FAC molecules to lipid 
raft (Fig. 5.15), suggesting that emodin is likely to disrupt the integrin signaling 
pathway by induction of cholesterol depletion in lipid raft. Lastly and more 
importantly, cholesterol replenishment was able to prevent the decrease of cell 
adhesion induced by emodin (Fig. 5.16). Taken together, these findings suggest that 
emodin likely targets on lipid raft cholesterol to disrupt the lipid raft clustering, 












Fig. 5.13 Emodin reduced the cholesterol content in lipid rafts. MDA-MB-231 
cells were treated with emodin (40 μM) or MBCD (2 mM) for 1 hr, followed by 30 min 
cholesterol replenishment (30 μg/ml). Then cells were planted onto FN-coated Petri 
dishes for 10 min. Detergent-insoluble fractions of cell lysates were separated and 
subjected to APCI/MS analysis of cholesterol content, as described in Materials and 
Methods. Data were presented as relative content comparing to non-emodin treated 








































Fig. 5.14 Emodin reduced the sphingolipids content in lipid rafts, which could be 
restored by cholesterol replenishment. MDA-MB-231 cells were treated with emodin 
(40 μM) or MBCD (2 mM) for 1 hr, followed by 30 min cholesterol replenishment (30 
μg/ml). Then cells were planted onto FN-coated Petri dishes for 10 min. 
Detergent-insoluble fractions of cell lysates were separated and subjected to lipid 
profile analysis, as described in Materials and Methods. Data were presented as 
relative content comparing to non-emodin treated control group (mean ± SD from 


























Fig. 5.15 Cholesterol replenishment prevented the adverse effect of emodin on 
lipid rafts-associated integrin signaling. MDA-MB-231 cells were treated with emodin 
(40 μM) or MBCD (2mM) for 1 hr, followed by 30 min cholesterol replenishment (30 
μg/ml). Then cell were planted onto FN-coated Petri dishes for 10 min. 
Detergent-insoluble fractions were subjected to 10% SDS-PAGE and immunoblotted 

























Fig. 5.16 Cholesterol replenishment prevented the adverse effect of emodin on cell 
adhesion. MDA-MB-231 cells were treated with emodin (40 μM) or MBCD (2mM) 
for 1 hr, followed by 30 min cholesterol replenishment (30 μg/ml). Cell adhesion assay 
was conducted as described in Materials and Methods. Data are presented as means ± 
SD from three independent experiments and expressed as percentage of the 


























Cell adhesion, together with cell migration and invasion, is an essential biological 
process that is involved in cancer metastasis [Woodhouse et al., 1997]. Interruption of 
cell adhesion has been considered as an important strategy for prevention and 
treatment of cancer metastasis. In this part of study, the inhibitory effect of emodin on 
adhesion of various human cancer cells was characterized. This inhibition is likely due 
to its disruptive effect on the components of membrane lipid rafts, thus inhibiting the 
lipid rafts-associated integrin signaling pathway.  
It is well established that once the malignant cells have detached from the primary 
tumor, they might reach an ectopic site and adhere to the meshwork of ECM, which 
contains various components, such as fibronectin, collagen and laminin. Besides, cell 
adhesion not only provides the structural anchorage for a cell, but also mediates 
important survival signals to the cell [Woodhouse et al., 1997; Bogenrieder and Herlyn, 
2003]. Failed attachment of malignant cells at a new site might frequently lead to the 
immediate initiation of apoptosis [Re et al., 1994]. In this part of study, emodin 
displays potent inhibitory effect on cell adhesion in various cancer cells, suggesting 
that this inhibition is not cell type specific. Notably, the results also demonstrated that 
emodin inhibits cell adhesion not merely to fibronectin, but also collagen I and laminin, 
suggesting that this inhibitory potential applies to a broad spectrum of ECM. At 
present, a number of cell adhesion inhibitors have been actively investigated, such as 
gefitinib [Shintani et al., 2003] and inositol hexaphosphate [Tantivejkul et al., 2003]. 
Furthermore, several cyclic peptide inhibitors and antibodies which block cell-matrix 
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interaction, such as cilengitide and vitaxin, are now being tested in clinical Phase I/II 
trials [Jin and Varner, 2004]. Therefore, taken together with the previous findings on 
emodin’s potent inhibitory effect on cancer cell invasion and migration, emodin 
appears to be a strong candidate for developing as a therapeutic agent to prevent cancer 
metastasis. 
Integrins are a large family of adhesion molecules on cell membrane responsible for 
cell attachment to ECM proteins. Integrin are heterodimeric receptor complexes which 
are composed of noncovalently associated α and β chains [Hynes, 2002]. 
Integrin-ECM interactions result in signaling cascades which promote both cell 
adhesion and spreading. Both integrin-mediated cell attachment and spreading are 
necessary for cell survival for many cell types and loss of adhesion causes apoptosis 
[Re et al., 1994]. Abnormalities and improper localization of these integrins at the cell 
surface have been observed in mammalian cancer cells and are believed to be closely 
related to their metastatic behavior [Tawil et al., 1996; Shaw, 1999; Mercurio et al., 
2001]. Since emodin does not directly affect integrin-ligand binding (Fig. 5.5), and no 
significant integrin expression change was observed after emodin treatment (Fig. 5.6), 
the possible effect of emodin on the integrin-initiated signaling pathway was then 
investigated. There are several key steps involved in this signaling pathway, including 
integrin receptor clustering or oligomerization. In fact, receptor oligomerization is a 
prerequisite for the activation of cellular signaling pathways for many types of 
receptors, including EGFR, TNFR, Fas/CD95 and integrins [Pande, 2000; Gulbins and 
Grassme, 2002; Jorissen et al., 2003]. Recent evidence suggests that integrins 
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clustering and functioning is regulated by their recruitment into discrete membrane 
rafts which are sphingolipids and cholesterol-rich microdomains [Leitinger and Hogg, 
2002]. One mode by which rafts transmit signals involves their coalescence into large 
platforms into which signaling proteins translocate and concentrate [Schuck and 
Simons, 2004]. Consistently, in the present study, after exposure to fibronectin, small 
membrane rafts were observed to coalesce into larger patches, while emodin inhibited 
this process to block the colocalization of integrin β1 with lipid rafts (Fig. 5.10-12). 
The newly created larger rafts would help to assemble different proteins to facilitate 
the signaling pathway. Thus, the inhibition of lipid raft clustering by emodin might be 
the underlying mechanism leading to the suppression of integrin clustering, FAC 
formation and eventually cell adhesion. Although the molecular mechanisms of 
integrin-lipid raft interactions are yet unclear, both cholesterol and sphingolipids, two 
essential components of lipid rafts, have been reported to play specific roles in 
regulating the integrin functions [Pande, 2000]. Therefore, to further explore the 
mechanism involved in the disruptive effect of emodin on lipid raft, the possible 
changes of cholesterol and sphingolipids within lipid rafts was investigated.  
As a neutral lipid, cholesterol accumulates in lipid rafts [Lawrence et al., 2003]. 
The hydrogen-bonding between 3-OH group of cholesterol and the amide group of 
sphingolipids contributes to the formation of sphingolipid-cholesterol liquid ordered 
domains and their resistance to non-ionic detergent extraction [Brown, 1998]. 
Lawrence et al recently reported, using model membranes, that moderate increases of 
membrane cholesterol (10-20%) lead to the decrease in the number of isolated rafts 
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and the formation of larger rafts [Lawrence et al., 2003]. Reduction of the cholesterol 
concentration in the plasma membrane can lead to the loss of signaling function of 
lipid rafts [Xavier et al., 1998]. The results showed that emodin decreases the 
cholesterol level in the detergent-insoluble fractions, and consequently suppresses 
lipid raft coalescence and cell adhesion (Fig. 5.11 and Fig. 5.13). Although it is not 
clear how emodin causes the reduction of cholesterol content in insoluble fraction of 
plasma membrane, one possible explanation is that emodin resides at the upper half of 
the phospholipid hydrocarbon chains in model membranes [Alves et al., 2004], thus 
affecting the tight interaction between cholesterol and sphingomyelins, and finally 
excluding cholesterol from lipid rafts.  
On the other hand, sphingolipid, typified by sphingomyelin, is one of the major 
classes of membrane phospholipids. It is composed of a lipid moiety, ceramide, which 
is embedded in the outer leaflet of that bilayer, and a sugar part that faces the 
extracellular space [Ichikawa and Hirabayashi, 1998]. Several reports have 
highlighted that sphingolipids are associated with integrins, and are capable of 
modulating their activity [Yates and Rampersaud, 1998; Pande, 2000]. Besides, 
ceramide, a major metabolic product of sphingomyelins, is reported to increase the 
tight packing of the acyl chains in the bilayer, promote stabilization of raft formation 
and provide the driving force for coalescence of rafts into platforms [Grassme et al., 
2003; Lacour et al., 2004]. In the present study, sphingomyelins, ceramides and 
ceramide glucosides were found to be decreased in the lipid raft fraction after emodin 
treatment (Fig. 5.14). These decreases might directly affect the tight packing and 
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stabilization of lipid rafts, thus impairing the signaling function of lipid rafts. 
Furthermore, cholesterol replenishment results confirmed that cholesterol 
contributes to the inhibition of cell adhesion by emodin. Replenishment of cholesterol 
not only restored the cholesterol level in the lipid rafts (Fig. 5.13), but also the content 
of sphingomyelins and ceramides decreased by emodin (Fig. 5.14). This suggests that 
emodin-induced reduction of these sphingolipids in membrane rafts is likely to be the 
result of the disorganization in the lipid raft domains brought by the removal of 
cholesterol. Meanwhile, cholesterol replenishment also recovers the translocation of 
integrin β1 and FAC molecules into raft fraction (Fig. 5.15), and eventually reverses 
the inhibitory effect of emodin on cell adhesion (Fig. 5.16). These findings further 
demonstrate that the decrease of cholesterol in lipid rafts is critical in mediating the 
disruptive effect of emodin on the lipid raft-associated integrin signaling and cell 
adhesion.  
Collectively, in this part of study, novel evidence was provided that emodin 
displays significant inhibitory effect on cell adhesion in various cancer cells. Such an 
inhibitory effect by emodin is through cholesterol decrease in lipid rafts, and 
subsequent suppression of the lipid raft-associated integrin signaling pathway. In 
previous chapters, emodin has been shown to possess strong effect against tumor cell 
migration and invasion. Taken together, these findings suggest that emodin, which 
potently interferes with tumor metastasis at all three critical steps, could be of 

























Emodin is one of the major active components contained in rhubarb, which has 
been popularly used as a laxative in traditional Chinese medicine for centuries. 
Emodin has been shown to display anti-viral, anti-microbial, hepatoprotective, 
anti-inflammatory and anti-ulcerogenic effects [Huang et al., 1992; Minyi, 1992; Lin 
et al., 1996]. In recent years, the anti-cancer activity of emodin has been well studied, 
using both in vitro cell and in vivo animal models [Chan et al., 1993; Zhang et al., 
1995; Chang et al., 1996; Cha et al., 2005]. One of main mechanisms involved is the 
strong inhibitory effect of emodin on several critical kinases, such as Her-2/neu 
kinase [Zhang et al., 1995; Zhang et al., 1998], CKII [Yim et al., 1999], and PKC 
[Jinsart et al., 1992]. Meanwhile, a number of recent studies on emodin were focused 
on its induction of apoptosis and the mechanisms involved [Lee, 2001a; Chen et al., 
2002; Srinivas et al., 2003]. It is reported that emodin induces apoptosis mainly 
through the mitochondrial pathway, which is mediated by ROS generated from the 
semiquinone [Jing et al., 2002; Su et al., 2005]. On the other hand, despite the fact 
that its anti-cancer properties have been well investigated, the effect of emodin 
against tumor metastasis is poorly understood. So far, no systematic study has been 
carried out to examine its effect against tumor metastasis and the molecular 
mechanism involved.  
Tumor metastasis is the most devastating aspect of malignant neoplasms. It is a 
process by which cancer spreads from the place at which it first arose as a primary 
tumor to distant locations in the body. This process consists of a complex cascade of 
interdependent steps, such as intravasation by tumor cells, circulation in lymph and 
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blood vascular systems, extravasation, and eventual proliferation as a secondary 
colony [Bogenrieder and Herlyn, 2003]. During these complex processes, cell 
adhesion, migration and invasion are essentially required for tumor metastasis: cell 
invasion and migration are critical for tumor cells to get across ECM barriers, and 
access the ectopic site to proliferate into a new colony [Yamazaki et al., 2005]; and 
cell adhesion allows cancer cells to attach to the ECM proteins and other cells 
[Hynes, 1999]. 
Currently, the occurrence for metastasis still leads to poor prognosis and death in 
patients with malignancy. Many attempts have been made to find promising agents 
against cancer metastasis. Although emodin has been shown to possess a number of 
anti-tumor activities, no systematic study has been carried out on its effect against 
tumor metastasis. Therefore, the objective of this study was to systematically 
investigate the anti-metastatic effect of emodin through the following studies: (i) 
inhibitory effect of emodin on cancer cell invasion (Chapter 3); (ii) inhibition of 
emodin on cancer cell migration (Chapter 4); and (iii) suppression of emodin on 
cancer cell adhesion (Chapter 5). 
6.1 Anti-metastatic potential of emodin – suppression of cancer cell invasion 
Tumor metastasis is the spreading of cancer cells from the primary site to new 
ectopic location through the circulation system. One of the key characteristics of 
malignant cells is their invasive ability to penetrate the tissue barriers, such as ECM 
[Bjorklund and Koivunen, 2005]. Prevention of cancer invasion and metastasis has 
become an important strategy in anticancer therapy. 
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Matrigel® matrix is a solubilized basement membrane preparation extracted from 
the Engelbreth-Holm-Swarm mouse sarcoma, a tumor rich in ECM proteins. Its 
major component is laminin, followed by collagen IV, heparan sulfate proteoglycans, 
entactin and nidogen. This is a popular experimental system to measure cell invasion 
of both malignant cells and normal cells. In this study, the effect of emodin on cancer 
cell invasion was tested using Matrigel®-coated transwell plates. It was found that at 
non-toxic concentration, emodin could markedly suppress TPA-induced cell invasion 
in a dose-dependent manner (Fig. 3.1 and 3.2).  
In the search of the molecular mechanisms involved in the inhibitory effect of 
emodin on cancer cell invasion, the role of MMPs was the focus of this part. MMPs 
are a group of endopeptidases, which are collectively capable of degrading all the 
essential ECM components [Khasigov et al., 2003]. Increased expression of MMPs is 
associated with tumor invasion and metastasis in different tissue origins [Kataoka et 
al., 2003]. It is recently accepted that a major role of MMPs during tumor invasion is 
not only to create a path by degrading the ECM barriers, but also to rearrange ECM 
to facilitate tumor cell migration [Khasigov et al., 2003]. Of the MMPs, a specific 
subset, the gelatinases (MMP-2 and MMP-9) have been under intensive investigation, 
especially in the area of cell invasion. These two gelatinases are sharing almost the 
same substrate specificity, but under rather different regulation of expression, 
glycosylation and proenzyme activation. For example, MMP-9 is a 92-kDa protein 
with two N-glycosylated sites in the prodomain and the catalytic domain, while the 
72-kDa MMP-2 is a nonglycosylated protein [Kotra et al., 2002]. Besides, MMP-2 is 
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rather constitutively expressed in tissues with only modest up or down regulation 
under various conditions, whereas stimulation of growth factors can result in many 
fold changes in mRNA and protein levels of MMP-9 [Bjorklund and Koivunen, 2005]. 
Due to these distinct characteristics, different responses of MMP-2 and MMP-9 
activity were observed in this study: the activity of MMP-9 was strongly increased 
after TPA stimulation, while MMP-2 showed no obvious changes (Fig. 3.3). Emodin 
significantly inhibited the activity and expression of MMP-9 induced by TPA. 
However, MMP-2 was not affected by emodin treatment (Fig. 3.3).  
The next question needed to be answered is how emodin down-regulates MMP-9 
expression. It has been well established that MMP-9 contains binding sites for AP-1 
and NF-κB transcription factors in its promoter region [Westermarck and Kahari, 
1999]. Therefore, the involvement of these two important transcription factors has 
been systematically investigated in emodin-induced MMP-9 down-regulation. In 
Chapter 3, emodin was shown to inhibit the phosphorylation of IκBα and 
translocation of p65 induced by TPA, as well as the transactivation and DNA binding 
activity of NF-κB (Fig. 3.9 and 3.10). However, so far, how emodin inhibits the 
activation of NF-κB is poorly understood. It was revealed that Rho GTPases could 
modulate the activity of NF-κB under certain circumstances. The human Cdc42 and 
Rac1 proteins efficiently induce the transcriptional activity of NF-κB by a mechanism 
that involves phosphorylation of IκBα and translocation of NF-κB proteins to the 
nucleus, but independent of the Ras GTPase and the Raf-1 kinase [Perona et al., 1997]. 
In Chapter 4, emodin was found to inhibit the EGF-induced activation of Cdc42 and 
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Rac1 (Fig. 4.10). Therefore, it is likely that emodin may inhibit the activity of NF-κB 
through suppressing Cdc42 and Rac1 activation. Further investigation is needed to 
test this hypothesis for a better understanding of the underlying mechanisms involved 
in the inhibitory effect of emodin on NF-κB activation.  
Besides NF-κB, another transcription factor, AP-1, also plays a critical role in 
regulating the expression of MMP-9 [Westermarck and Kahari, 1999]. In the present 
study, emodin was found to noticeably suppress the DNA-binding and transcriptional 
activity of AP-1 induced by TPA (Fig. 3.4 and 3.5). Furthermore, emodin inhibited 
TPA-induced phosphorylation of c-Jun (Fig. 3.6), a major component of AP-1. In 
searching of the underlying mechanisms involved, the effect of emodin on MAPKs, 
which are closely related with c-Jun phosphorylation and AP-1 transactivation 
[Cowley et al., 1994], was examined. Emodin suppressed TPA-induced 
phosphorylation of ERK and JNK, but not p38. Meanwhile, SP600125, a specific 
JNK inhibitor and PD98059, a specific ERK inhibitor, both effectively inhibited 
TPA-induced MMP-9 expression and cell invasion (Fig. 3.12 and 3.13). Taken 
together, it is believed that emodin may suppress TPA-induced MMP-9 expression and 
cancer cell invasion through JNK and ERK pathways.  
As one of the strategies of MMP inhibition in anticancer therapy, inhibition of 
MMP synthesis can be achieved through targeting mRNA with ribozymes, or 
transfecting cells with antisense mRNA or oligonucleotides. For example, 
down-regulation of MMP-9 expression by stable transfection of antisense MMP-9 
mRNA resulted in marked reductions in invasiveness of glioblastoma cells 
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[Kondraganti et al., 2000]. Inhibition of MMP-9 expression using specific ribozyme 
blocked metastasis in a rat sarcoma model system [Hua and Muschel, 1996]. On the 
other hand, MMP expression can be decreased by inhibition of the signal-transduction 
pathways that induce MMP transcription [Bjorklund and Koivunen, 2005]. 
Accordingly, in this study, emodin was found to significantly suppress the expression 
and activity of MMP-9. This suppression is through inhibiting the AP-1 and NF-κB 
signaling and subsequent MMP-9 transcription. Similar evidence has been reported 
that inhibition of MMP-9 leads to suppression of invasiveness and metastasis of 
cancer cells, using various chemopreventive or chemotherapeutic agents such as 
genistein, aspirin, and penta-O-galloyl-β-D-glucose [Shao et al., 1998; Alhasan et al., 
2001; Abiru et al., 2002; Ho et al., 2002].  
Meanwhile, new strategies have been suggested for the future clinical trial of 
MMP inhibitors. The newly developed inhibitors can be administered for long time 
without side-effects; besides, they can be used for treating cancer at earlier stages, 
combined with other proteinase inhibitors [Pavlaki and Zucker, 2003]. In addition, a 
better and more comprehensive understanding of the regulatory mechanisms that 
control MMPs transcription, activation and inhibition may help to figure out new 
strategies for targeting MMPs, and finally lead to good clinical effect of MMPs 
inhibition in cancer. Although the current clinical trials of MMP inhibitors are not yet 
satisfying, more data are accumulating to support the development of promising 
therapeutic agents that block the synthesis of MMPs, prevent them from interacting 
with the molecules that direct their activities to the cell surface or inhibit their 
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enzyme activity [Bramhall et al., 2002; Pavlaki and Zucker, 2003]. In this case, 
emodin could be a strong candidate for developing new therapeutic drugs against 
tumor invasion and metastasis. 
6.2 Anti-metastatic potential of emodin – inhibition of cancer cell migration 
Cell migration is an important process not only during organ development, but 
also throughout life such as wound repairing and immune surveillance. Meanwhile, it 
is also essential in cancer metastasis, which results in the unrestrained ability of 
cancer cells to leave their primary site, invade surrounding tissue, and finally 
disseminate to secondary sites. Although the basic concepts in cell migration have 
been well established, the details how these events are regulated and executed are not 
quite clear yet. The major principle of cell migration is that cells must convert the 
intracellular forces generated by actin cytoskeleton rearrangement to cell body 
translocation [Lauffenburger and Horwitz, 1996]. In response to migratory signals, 
such as EGF, FBS, PDGF, cells might execute non-directional movement 
(chemokinesis) or directed migration along a chemical concentration gradient of the 
stimuli (chemotaxis) [Raftopoulou and Hall, 2004]. At the beginning stage of cell 
migration, certain cell structures are formed at the cell front: lamellipodia are broad 
flat membrane extensions and filopodia are cylindrical needle-like projections. Both 
are the result of actin polymerization [Schmitz et al., 2000].  
Due to the critical effect of migration during cancer metastasis, in Chapter 4, the 
effect of emodin on cell migration was examined using different cancer cells. The 
results show that emodin effectively suppresses EGF-induced cell migration. This 
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suppression is through inhibiting the PI3K-Cdc42/Rac1 pathways: EGF induced 
PI3K-mediated activation of Cdc42 and Rac1, and emodin targets on PI3K as one of 
the underlying mechanisms to suppress Cdc42 and Rac1 activation. In fact, during 
migration, Cdc42 and Rac1 are required, especially at the front of migrating cells, to 
regulate actin cytoskeleton rearrangement. The mechanisms regulating Cdc42 and 
Rac1 activation have been under extensive investigations, and PI3K pathway has 
emerged to be particularly important and widespread. Together with its lipid product 
PIP3, PI3K has been proved to be closely involved in controlling cell migration and 
polarity [Stephens et al., 2002]. Increase of PIP3 by PI3K activation results in 
enhanced Rac activation and obvious formation of lamellipodia and membrane 
ruffling in many cell types [Reif et al., 1996]. PIP3 promotes Rac1 activation possibly 
through a direct interaction with Rac GEFs. The PH domain of some GEFs can bind 
to phospholipids and this binding relieves an inhibitory interaction between the PH 
and DH (catalytic) domains of GEFs and thus activatse GEFs [Han et al., 1998; Abe 
et al., 2000]. PIP3 can also regulate PIX, which in turn activates Rac1 and promotes 
actin polymerization [Yoshii et al., 1999]. Besides PI3K, there are also other 
mechanisms to regulate the activation of Cdc42 and Rac1. Some growth factors can 
activate GEFs via tyrosine phosphorylation and subsequently activate Rac1 [Price 
and Collard, 2001]. This pathway might cooperate with the pathway requiring 
PI3K-mediated activation of certain GEFs. 
Besides suppressing the PI3K activity, emodin also disrupts the formation of 
Cdc42/Rac1 and PAK1 complex. This is another mechanism involved in the 
 169 
inhibitory effect of emodin on cell migration. PAK1 is identified as an essential 
effector of Rho GTPases. Several growth factors including EGF, PDGF, and HGF 
activate PAK1 via activation of Rho GTPases [Vadlamudi and Kumar, 2003]. 
Binding of GTP-bound GTPases to PAK1 stimulates its kinase activity via 
autophosphorylation. It is generally accepted that PAKs play an important role in a 
variety of cellular functions including cell motility, morphogenesis, angiogenesis, 
and survival. Activation of PAK1 has been shown to be critical in maintenance of the 
integrity of the motile leading edge, a process necessary for increased motility, and 
subsequent productive metastasis [Sells et al., 1999]. Expression of a kinase-dead 
PAK1 mutant in the highly invasive breast cancer cell lines MDA-MB-435 and 
MDA-MB-231 led to reduced activation of JNK/AP1, and reduced motility and 
invasiveness [Adam et al., 2000]. In the present study, emodin has been shown to 
inhibit the complex formation of activated Cdc42/Rac1 and PAK1, and subsequent 
suppression of PAK1 activation and actin cytoskeleton reorganization, and finally the 
decreased cell mobility.  
It is worth mentioning that, although the microtubule cytoskeleton is not essential 
during cell migration over short distances, long range migration requires 
reorganization of microtubule cytoskeleton to stabilize the cell polarity. Recently it is 
reported that Cdc42 and Rac1 also play a role in regulating the microtubule 
cytoskeleton [Wittmann and Waterman-Storer, 2001]. Cdc42 is critical in defining 
cell polarity with respect to the external stimuli. Suppression of Cdc42 inhibited the 
chemotaxis towards a gradient of colony-stimulating factor-1 in macrophage cells 
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[Ridley, 2001]. Besides, the positive feedback loop between PIP3 and Rac1 is 
involved in establishing cell asymmetry and polarity [Weiner et al., 2002]. The 
polarization by reorganization of the microtubule cytoskeleton and centrosome might 
facilitate cell migration through directing transport pathways to the leading edge of 
migrating cells, which is critical for efficient and persistent long-range migration 
[Sasahara et al., 2002]. Cdc42 is reported to modulate this orientation of 
microtubules, at least partially, through the Cdc42-Par6/PKCξ-GSK-3-APC 
pathways [Etienne-Manneville and Hall, 2003]. Based on these observations and 
those findings that emodin inhibits the activation of Cdc42 and Rac1, it is 
hypothesized that emodin might display certain effect on microtubule cytoskeleton, 
and this hypothesis is still under investigations. 
6.3 Anti-metastatic potential of emodin – interference of cancer cell adhesion 
Cancer cell invasion, migration and adhesion are three critical steps in cancer 
metastasis [Bogenrieder and Herlyn, 2003]. The studies discussed above have 
examined the effect of emodin on cancer cell invasion and migration. Therefore, in 
Chapter 5, the effect of emodin on cancer cell adhesion was the focus of this part. 
The basic steps of adhesion involve cell encounter with substrate, integrin ligand 
binding, cell spreading, formation of adhesion contacts, and generation of stress 
fibers [Carragher and Frame, 2004]. The major means of cell adhesion to ECM 
substrates utilizes receptors of the integrin family [Hynes, 2002]. In the present study, 
emodin shows significant inhibition of cancer cell adhesion to a number of ECM 
molecules, such as fibronectin, collagen and laminin (Fig. 5.2). Besides, similar 
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inhibitory effect was observed in several cancer cell lines from different tissue 
origins (Fig. 5.1). Furthermore, it was demonstrated that this inhibitory effect might 
be due to a common mechanism that emodin suppresses the coalescence of lipid raft 
(Fig. 5.11). Since lipid raft clustering is a common early event during 
integrin-mediated cell adhesion, this might help to explain how emodin can display 
strong inhibition on adhesion in various cancer cells and upon different ECM 
proteins. Taken together with a previous study showing that emodin inhibited the 
adhesion of HL-60 cells to human umbilical vein endothelial cell monolayers 
[Kumar et al., 1998], these results suggest that emodin might be able to block the 
adhesion of metastatic cancer cells to ECM proteins and endothelial cells in the 
vessel wall, two critical steps during cancer cell adhesion and metastasis.  
Integrin engagement not only links the cells with ECM or other cells, but also 
induces the formation of membrane extensions that are required for cell spreading or 
protrusion of cells into sheets of other cells. During this process, integrins and 
associated proteins are organized into large multi-protein aggregates, which are the 
sites of close contact between the plasma membrane and the ECM substrate where 
integrins bind to F-actin through cytoskeletal adaptor proteins such as paxillin, 
vinculin and others [Burridge and Chrzanowska-Wodnicka, 1996]. Consistently, in 
this study, the FAC formation was observed after attachment of cells to fibronectin 
(Fig. 5.4). Besides, the FAC formation was found to be a dynamic and complex 
process, including recruitment of FAK to integrins, phosphorylation of FAK, and 
association of other FAC proteins to the complex. Emodin was found to effectively 
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inhibit these steps: it inhibited the association of FAK with integrin β1, a common 
subunit involved in integrin-ECM interaction (Fig. 5.7); subsequently, emodin 
suppressed the phosphorylation of FAK Y397 (Fig. 5.8) and the association of other 
FAC proteins, such as paxillin and vinculin, with the complex (Fig. 5.9 and 5.10). 
These results clearly indicate the disruptive effect of emodin on the 
integrin-mediated signaling pathway. 
In searching of underlying mechanisms involved, emodin was found to strongly 
suppress the integrin clustering (Fig. 5.11), thus inhibiting the subsequent signaling 
cascade leading to adhesion. In fact, receptor oligomerization and clustering is the 
mechanism responsible for the activation of most transmembrane receptors, including 
integrins [Schlessinger, 2000]. For these receptors, oligomerization and clustering 
follows ligand binding and leads to their subsequent activation. These receptors cluster 
in particular detergent-resistant membrane micro-domains known as lipid rafts, where 
they may make contact with various signaling molecules [Simons and Toomre, 2000]. 
Partitioning of receptors into rafts results in a new micro-environment, where their 
phosphorylation state can be modified by local kinases and phosphatases, thus 
modulating downstream signaling. Raft clustering could also be involved in the 
amplification and transduction of various signals [Simons and Toomre, 2000]. Lipid 
rafts consist of dynamic assemblies of cholesterol and sphingolipids in the exoplasmic 
leaflet of the lipid bilayer. If cholesterol or sphingolipids are depleted from membranes, 
lipid rafts are dissociated, and previously associated proteins are no longer in rafts. 
Consistently, in this study, emodin was found to reduce the cholesterol level in the 
 173 
membrane lipid rafts (Fig. 5.13). This reduction leads to significant suppression of 
lipid raft and integrin clustering (Fig. 5.11), and subsequent focal adhesion formation 
(Fig. 5.4) and cell adhesion (Fig. 5.1).  
Of course, other effects on cell metabolism can not be discarded since emodin 
might be able to easily cross membranes and affect certain signaling pathways. For 
instance, it is believed that integrin-mediated adhesion is a regulated process, which 
various stimuli can induce intracellular signaling cascades that change the molecular 
interactions at the integrin cytoplasmic domains. Since integrins are normally 
expressed on the cell surface in a low-affinity state [Hynes, 2002], these activating 
signals could be transmitted from the integrin cytoplasmic face to the extracellular 
domain, thereby increasing the affinity/avidity of the receptors for ligands (integrin 
activation) [Liddington and Ginsberg, 2002]. Among these signaling pathways, PI3K 
and PKC are reported to play a role in regulating integrin ligand binding 
affinity/avidity through this inside-out regulating mechanism [Shattil and Newman, 
2004]. In Chapter 4, emodin has been shown to display disruptive effect on the PI3K 
signaling pathway. Besides, emodin was previously reported to suppress PKC 
activity [Fredenhagen et al., 1995]. Therefore, these inhibitory characters might also 
contribute to the inhibitory effect of emodin on integrin-mediated adhesion, through 
suppressing the inside-out mechanism of integrin activation. 
Collectively, in the present study, emodin displays remarkable inhibitory effect 
on these crucial and interdependent metastatic steps: invasion, migration, and 
adhesion. Many signaling pathways complimentarily synergize these processes. For 
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example, besides mediating stable cell-matrix adhesion, integrins play a crucial role 
in cell migration as well [Ridley et al., 2003]; the gelatinases, MMP-2 and MMP-9, 
also accumulate into focal adhesions and play a role in regulating the cell adhesion 
[Partridge et al., 1997]. Thus, the inhibitory effect of emodin on cancer cell invasion, 
migration and adhesion might be due to its suppression on several key junctures of 
tumor metastatic signaling network, such as MMP-9 expression, PI3K signaling, 
Cdc42/Rac1 activation, and integrin pathways. Targeting on multiple molecular 
targets, emodin might be an attractive candidate of chemotherapy to interfere with 
tumor metastasis.  
6.4 Summary and Conclusions 
The anti-metastatic property of emodin, a major anthraquinone component 
contained in rhubarb, has been systematically investigated in this study (Fig. 6.1). 
The whole study can be divided into three parts: (i) suppressive effect of emodin on 
cancer cell invasion; (ii) inhibitory effect of emodin on cancer cell migration; and (iii) 
suppression of emodin on cancer cell adhesion.  
The major findings of this study are:  
(1) Emodin suppresses cancer cell invasion through down-regulation of 
MMP-9 expression via the following mechanisms: 
z Inhibition of the transactivation and DNA binding activity of NF-κB and 
AP-1, two major transcription factors that regulate MMP-9 expression; 
z Decrease of the phosphorylation of ERK and JNK, which are closely 
related to AP-1 activation; 
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z Suppression of IκBα phosphorylation and degradation, which is 
essential to NF-κB activation; 
(2) Emodin inhibits EGF-induced cancer cell migration via: 
z Interference with PI3K signaling pathway; 
z Suppression of activation of Cdc42 and Rac1 and the corresponding 
cytoskeleton changes; 
z Inhibition of the formation of Cdc42/Rac1 and PAK complex; 
(3) Emodin suppresses cancer cell migration through the following 
mechanisms:  
z Interference with the formation of focal adhesion complex; 
z Inhibition of integrin clustering; 
z Decrease of cholesterol level in lipid rafts and suppression of raft 
clustering. 
As discussed earlier, cancer cell adhesion, migration and invasion are distinct but 
coordinately regulated process critical for cancer metastasis [Uhm et al., 1997]. The 
new findings from this study strongly demonstrate that emodin potentially interferes 
with tumor metastatic progression at several pivotal points: (i) suppression of cancer 
cell invasion; (ii) inhibition of cancer cell migration; and (iii) interference with 
cancer cell adhesion. Taken together with the previous findings that emodin inhibits 
the angiogenesis process [Ljubimov et al., 2004], it is thus believed that emodin is a 
promising candidate that can be developed into a chemotherapeutic agent for 
preventing cancer metastasis.  
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Cancer metastasis is a highly complicated series of intertwined events involving 
invasion, migration, adhesion, and angiogenesis. Thus, in vivo studies, including the 
use of mouse models, will be necessary to verify the effects of emodin as a therapeutic 
agent for the prevention and treatment of tumor metastasis. In order to reach the 
magnitude and specificity of its effective cancer treatment, collaborative 
investigations with input from disciplines such as oncology, chemistry and 
pharmacology will be required. Such studies will eventually contribute to a more 
complete understanding of the inhibitory effect of emodin on tumor metastasis, and as 
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